Vaccines or candidate vaccines used to prevent or treat TUBERCULOSIS.
Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM.
An active immunizing agent and a viable avirulent attenuated strain of Mycobacterium tuberculosis, var. bovis, which confers immunity to mycobacterial infections. It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity.
MYCOBACTERIUM infections of the lung.
A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation.
The bovine variety of the tubercle bacillus. It is called also Mycobacterium tuberculosis var. bovis.
Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.
Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.
Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.
Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease.
Substances elaborated by bacteria that have antigenic activity.
Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins.
An infection of cattle caused by MYCOBACTERIUM BOVIS. It is transmissible to man and other animals.
Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease.
Any immunization following a primary immunization and involving exposure to the same or a closely related antigen.
Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers.
One of several skin tests to determine past or present tuberculosis infection. A purified protein derivative of the tubercle bacilli, called tuberculin, is introduced into the skin by scratch, puncture, or interdermal injection.
Live vaccines prepared from microorganisms which have undergone physical adaptation (e.g., by radiation or temperature conditioning) or serial passage in laboratory animal hosts or infected tissue/cell cultures, in order to produce avirulent mutant strains capable of inducing protective immunity.
Two or more vaccines in a single dosage form.
Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.
A genus of gram-positive, aerobic bacteria. Most species are free-living in soil and water, but the major habitat for some is the diseased tissue of warm-blooded hosts.
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent or treat AIDS. Some vaccines containing antigens are recombinantly produced.
Proteins found in any species of bacterium.
The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES.
Vaccines consisting of one or more antigens that stimulate a strong immune response. They are purified from microorganisms or produced by recombinant DNA techniques, or they can be chemically synthesized peptides.
Semisynthetic vaccines consisting of polysaccharide antigens from microorganisms attached to protein carrier molecules. The carrier protein is recognized by macrophages and T-cells thus enhancing immunity. Conjugate vaccines induce antibody formation in people not responsive to polysaccharide alone, induce higher levels of antibody, and show a booster response on repeated injection.
An acute form of TUBERCULOSIS in which minute tubercles are formed in a number of organs of the body due to dissemination of the bacilli through the blood stream.
Enzymes from the transferase class that catalyze the transfer of acyl groups from donor to acceptor, forming either esters or amides. (From Enzyme Nomenclature 1992) EC 2.3.
Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role.
Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes.
Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood.
The dormant form of TUBERCULOSIS where the person shows no obvious symptoms and no sign of the causative agent (Mycobacterium tuberculosis) in the SPUTUM despite being positive for tuberculosis infection skin test.
Infection of the lymph nodes by tuberculosis. Tuberculous infection of the cervical lymph nodes is scrofula.
Vaccines made from antigens arising from any of the four strains of Plasmodium which cause malaria in humans, or from P. berghei which causes malaria in rodents.
Inbred BALB/c mice are a strain of laboratory mice that have been selectively bred to be genetically identical to each other, making them useful for scientific research and experiments due to their consistent genetic background and predictable responses to various stimuli or treatments.
A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research.
Tuberculosis of the bones or joints.
A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.
TUBERCULOSIS that involves any region of the GASTROINTESTINAL TRACT, mostly in the distal ILEUM and the CECUM. In most cases, MYCOBACTERIUM TUBERCULOSIS is the pathogen. Clinical features include ABDOMINAL PAIN; FEVER; and palpable mass in the ileocecal area.
Osteitis or caries of the vertebrae, usually occurring as a complication of tuberculosis of the lungs.
Vaccines or candidate vaccines used to prevent PAPILLOMAVIRUS INFECTIONS. Human vaccines are intended to reduce the incidence of UTERINE CERVICAL NEOPLASMS, so they are sometimes considered a type of CANCER VACCINES. They are often composed of CAPSID PROTEINS, especially L1 protein, from various types of ALPHAPAPILLOMAVIRUS.
Tuberculosis of the skin. It includes scrofuloderma and tuberculid, but not LUPUS VULGARIS.
Vaccines or candidate vaccines used to prevent infection with NEISSERIA MENINGITIDIS.
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
Inbred C57BL mice are a strain of laboratory mice that have been produced by many generations of brother-sister matings, resulting in a high degree of genetic uniformity and homozygosity, making them widely used for biomedical research, including studies on genetics, immunology, cancer, and neuroscience.
Material coughed up from the lungs and expectorated via the mouth. It contains MUCUS, cellular debris, and microorganisms. It may also contain blood or pus.
Vaccines or candidate vaccines containing inactivated hepatitis B or some of its component antigens and designed to prevent hepatitis B. Some vaccines may be recombinantly produced.
A live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had measles or been immunized with live measles vaccine and have no serum antibodies against measles. Children are usually immunized with measles-mumps-rubella combination vaccine. (From Dorland, 28th ed)
Tuberculosis of the serous membrane lining the thoracic cavity and surrounding the lungs.
Tuberculosis resistant to ISONIAZID and RIFAMPIN and at least three of the six main classes of second-line drugs (AMINOGLYCOSIDES; polypeptide agents; FLUOROQUINOLONES; THIOAMIDES; CYCLOSERINE; and PARA-AMINOSALICYLIC ACID) as defined by the CDC.
A general term for MYCOBACTERIUM infections of any part of the UROGENITAL SYSTEM in either the male or the female.
A suspension of killed Bordetella pertussis organisms, used for immunization against pertussis (WHOOPING COUGH). It is generally used in a mixture with diphtheria and tetanus toxoids (DTP). There is an acellular pertussis vaccine prepared from the purified antigenic components of Bordetella pertussis, which causes fewer adverse reactions than whole-cell vaccine and, like the whole-cell vaccine, is generally used in a mixture with diphtheria and tetanus toxoids. (From Dorland, 28th ed)
A form of bacterial meningitis caused by MYCOBACTERIUM TUBERCULOSIS or rarely MYCOBACTERIUM BOVIS. The organism seeds the meninges and forms microtuberculomas which subsequently rupture. The clinical course tends to be subacute, with progressions occurring over a period of several days or longer. Headache and meningeal irritation may be followed by SEIZURES, cranial neuropathies, focal neurologic deficits, somnolence, and eventually COMA. The illness may occur in immunocompetent individuals or as an OPPORTUNISTIC INFECTION in the ACQUIRED IMMUNODEFICIENCY SYNDROME and other immunodeficiency syndromes. (From Adams et al., Principles of Neurology, 6th ed, pp717-9)
A pyrazine that is used therapeutically as an antitubercular agent.
Substances obtained from various species of microorganisms that are, alone or in combination with other agents, of use in treating various forms of tuberculosis; most of these agents are merely bacteriostatic, induce resistance in the organisms, and may be toxic.
Vaccines or candidate vaccines containing antigenic polysaccharides from Haemophilus influenzae and designed to prevent infection. The vaccine can contain the polysaccharides alone or more frequently polysaccharides conjugated to carrier molecules. It is also seen as a combined vaccine with diphtheria-tetanus-pertussis vaccine.
A suspension of formalin-inactivated poliovirus grown in monkey kidney cell tissue culture and used to prevent POLIOMYELITIS.
Vaccines or candidate vaccines used to prevent and treat RABIES. The inactivated virus vaccine is used for preexposure immunization to persons at high risk of exposure, and in conjunction with rabies immunoglobulin, for postexposure prophylaxis.
Vaccines or candidate vaccines used to prevent infection with ROTAVIRUS.
Vaccines or candidate vaccines used to prevent infection with VIBRIO CHOLERAE. The original cholera vaccine consisted of killed bacteria, but other kinds of vaccines now exist.
Infection of the spleen with species of MYCOBACTERIUM.
Tuberculous infection of the eye, primarily the iris, ciliary body, and choroid.
Vaccines used to prevent TYPHOID FEVER and/or PARATYPHOID FEVER which are caused by various species of SALMONELLA. Attenuated, subunit, and inactivated forms of the vaccines exist.
A live VACCINIA VIRUS vaccine of calf lymph or chick embryo origin, used for immunization against smallpox. It is now recommended only for laboratory workers exposed to smallpox virus. Certain countries continue to vaccinate those in the military service. Complications that result from smallpox vaccination include vaccinia, secondary bacterial infections, and encephalomyelitis. (Dorland, 28th ed)
Immunoglobulins produced in a response to BACTERIAL ANTIGENS.
Immunoglobulins produced in response to VIRAL ANTIGENS.
Infection of the LIVER with species of MYCOBACTERIUM, most often MYCOBACTERIUM TUBERCULOSIS. It is characterized by localized small tuberculous miliary lesions or tumor-like mass (TUBERCULOMA), and abnormalities in liver function tests.
MYCOBACTERIUM infections of the female reproductive tract (GENITALIA, FEMALE).
A live, attenuated varicella virus vaccine used for immunization against chickenpox. It is recommended for children between the ages of 12 months and 13 years.
A rapid-growing, nonphotochromogenic species of MYCOBACTERIUM originally isolated from human smegma and found also in soil and water. (From Dorland, 28th ed)
A vaccine consisting of DIPHTHERIA TOXOID; TETANUS TOXOID; and whole-cell PERTUSSIS VACCINE. The vaccine protects against diphtheria, tetanus, and whooping cough.
An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863)
Vaccines used to prevent infection by MUMPS VIRUS. Best known is the live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had mumps or been immunized with live mumps vaccine. Children are usually immunized with measles-mumps-rubella combination vaccine.
Schedule giving optimum times usually for primary and/or secondary immunization.
Vaccines or candidate vaccines used to prevent infection with hepatitis A virus (HEPATOVIRUS).
A combined vaccine used to prevent MEASLES; MUMPS; and RUBELLA.
Vaccines or candidate vaccines used to prevent STREPTOCOCCAL INFECTIONS.
A treatment method in which patients are under direct observation when they take their medication or receive their treatment. This method is designed to reduce the risk of treatment interruption and to ensure patient compliance.
Infection of the ENDOCRINE GLANDS with species of MYCOBACTERIUM, most often MYCOBACTERIUM TUBERCULOSIS.
Tuberculosis of the brain, spinal cord, or meninges (TUBERCULOSIS, MENINGEAL), most often caused by MYCOBACTERIUM TUBERCULOSIS and rarely by MYCOBACTERIUM BOVIS. The infection may be limited to the nervous system or coexist in other organs (e.g., TUBERCULOSIS, PULMONARY). The organism tends to seed the meninges causing a diffuse meningitis and leads to the formation of TUBERCULOMA, which may occur within the brain, spinal cord, or perimeningeal spaces. Tuberculous involvement of the vertebral column (TUBERCULOSIS, SPINAL) may result in nerve root or spinal cord compression. (From Adams et al., Principles of Neurology, 6th ed, pp717-20)
Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).
Vaccines or candidate vaccines used to prevent ANTHRAX.
Vaccines or candidate vaccines used to prevent infection with DENGUE VIRUS. These include live-attenuated, subunit, DNA, and inactivated vaccines.
Tuberculosis involving the larynx, producing ulceration of the VOCAL CORDS and the LARYNGEAL MUCOSA.
Vaccines using VIROSOMES as the antigen delivery system that stimulates the desired immune response.
Deoxyribonucleic acid that makes up the genetic material of bacteria.
Infection of the KIDNEY with species of MYCOBACTERIUM.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Any vaccine raised against any virus or viral derivative that causes hepatitis.
A live vaccine containing attenuated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used for routine immunization of children against polio. This vaccine induces long-lasting intestinal and humoral immunity. Killed vaccine induces only humoral immunity. Oral poliovirus vaccine should not be administered to immunocompromised individuals or their household contacts. (Dorland, 28th ed)
Vaccine used to prevent YELLOW FEVER. It consists of a live attenuated 17D strain of the YELLOW FEVER VIRUS.
A suspension of killed Yersinia pestis used for immunizing people in enzootic plague areas.
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
Suspensions of attenuated or killed fungi administered for the prevention or treatment of infectious fungal disease.

Comparative affects of plasmid-encoded interleukin 12 and interleukin 18 on the protective efficacy of DNA vaccination against Mycobacterium tuberculosis. (1/350)

Protective immunity against Mycobacterium tuberculosis infection requires the induction and maintenance of mycobacteria-specific, IFN-gamma-secreting CD4+ and CD8+ T lymphocytes. The development of Th1-like T cells is promoted by the early secretion and synergistic action of interleukin (IL)-12 and IL-18. This study compares the effects of plasmid-encoded IL-12 and IL-18 on the immunogenicity and protective efficacy of a DNA vaccine expressing the M. tuberculosis-secreted protein antigen 85B (DNA-85B). Co-immunization with either IL-12- or IL-18-expressing plasmids augmented the IFN-gamma-secreting T-cell response, and the maximum effect was observed with plasmids encoding both cytokines. Further the IL-12, but not the IL-18-expressing plasmid, significantly increased the protective efficacy of DNA-85B against pulmonary M. tuberculosis infection. Therefore co-administration of plasmid-encoded cytokines provides a potential method for optimizing the protective efficacy of DNA vaccination against tuberculosis.  (+info)

Immunogenicity of Mycobacterium tuberculosis RD1 region gene products in infected cattle. (2/350)

Current immuno-diagnostic tests for the detection of Mycobacterium bovis infection in cattle rely on the use of tuberculin PPD as antigens. However, the use of a cattle vaccine is effectively prohibited because BCG, the only potentially available cattle TB vaccine, compromises the current tuberculin test. The main objective of this study was to identify specific antigens, which could increase the test sensitivity to levels achieved with tuberculin. Our approach utilized the availability of the genome sequences of Mycobacterium tuberculosis and BCG by applying principles of comparative genomics to the identification of species-specific antigens. Eight open-reading frames (Rv3871 to Rv3878) encoding for putative antigens in the RD1 region of the M. tuberculosis genome, which is deleted in all strains of BCG, were selected and screened in the form of pools of synthetic peptides for immunological reactivity (antigen induced proliferation and IFN-gamma secretion) with peripheral blood mononuclear cells from cattle experimentally infected with M. bovis. Our results confirm the immunodominant role of two RD1 region products, CFP-10 (Rv3874) and ESAT-6 (Rv3875). In addition, we were able to identify 3 more antigens (Rv3871, Rv3872 and Rv3873), which induced immunological reactivity in PBMC from more than 50%M. bovis of infected cattle.  (+info)

Production of avirulent mutants of Mycobacterium bovis with vaccine properties by the use of illegitimate recombination and screening of stationary-phase cultures. (3/350)

A better tuberculosis vaccine is urgently required to control the continuing epidemic. Molecular techniques are now available to produce a better live vaccine than BCG by producing avirulent strains of the Mycobacterium tuberculosis complex with known gene deletions. In this study, 1000 illegitimate recombinants of Mycobacterium bovis were produced by illegitimate recombination with fragments of mycobacterial DNA containing a kanamycin resistance gene. Eight recombinant strains were selected on the basis of their inability to grow when stationary-phase cultures were inoculated into minimal medium. Five of these recombinants were found to be avirulent when inoculated into guinea pigs. Two of the avirulent recombinants produced vaccine efficacy comparable to BCG against an aerosol challenge in guinea pigs with M. bovis. One of these recombinants had an inactivated glnA2 gene encoding a putative glutamine synthetase. Transcriptional analysis showed that inactivation of glnA2 did not affect expression of the downstream glnE gene. The other recombinant had a block of 12 genes deleted, including the sigma factor gene sigG. Two avirulent recombinants with an inactivated pckA gene, encoding phosphoenolpyruvate carboxykinase which catalyses the first step of gluconeogenesis, induced poor protection against tuberculosis. It is clear that live avirulent strains of the M. tuberculosis complex vary widely in their ability as vaccines to protect against tuberculosis. Improved models may be required to more clearly determine the difference in protective effect between BCG and potential new tuberculosis vaccines.  (+info)

Identification of novel Mycobacterium tuberculosis antigens with potential as diagnostic reagents or subunit vaccine candidates by comparative genomics. (4/350)

An independent review for the British government has concluded that the development of a cattle vaccine against Mycobacterium bovis holds the best long-term prospects for tuberculosis control in British herds. The development of complementary diagnostic tests to differentiate between vaccinated and infected animals is necessary to allow the continuation of test-and-slaughter-based control policies alongside vaccination. Vaccination with M. bovis bacillus Calmette-Guerin (BCG), the only available vaccine, results in tuberculin purified protein derivative sensitivity and has shown varying vaccine efficacies in cattle. Thus, identification of more-specific reagents to distinguish between vaccination and infection, as well as the identification of subunit vaccine candidates for improved tuberculosis vaccines, is a research priority. In the present study, we applied comparative genomics to identify M. bovis-Mycobacterium tuberculosis antigens whose genes had been deleted in BCG Pasteur. In total, 13 open reading frames (ORFs) from the RD1, RD2, and RD14 regions of the M. tuberculosis genome were selected. Pools of overlapping peptides spanning these ORFs were tested in M. bovis-infected (n = 22), BCG-vaccinated (n = 6), and unvaccinated (n = 10) control cattle. All were recognized in infected cattle, with responder frequencies varying between 16 and 86%. In particular, eight highly immunogenic antigens were identified whose potentials as diagnostic reagents or as subunit vaccines warrant further study (Rv1983, Rv1986, Rv3872, Rv3873, Rv3878, Rv3879c, Rv1979c, and Rv1769).  (+info)

Mapping of murine Th1 helper T-Cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis. (5/350)

BALB/c (H-2(d)) and C57BL/6 (H-2(b)) mice were infected intravenously with Mycobacterium tuberculosis H37Rv or vaccinated intramuscularly with plasmid DNA encoding each of the three mycolyl transferases Ag85A, Ag85B, and Ag85C from M. tuberculosis. Th1-type spleen cell cytokine secretion of interleukin-2 (IL-2) and gamma interferon (IFN-gamma) was analyzed in response to purified Ag85 components and synthetic overlapping peptides covering the three mature sequences. Tuberculosis-infected C57BL/6 mice reacted strongly to some peptides from Ag85A and Ag85B but not from Ag85C, whereas tuberculosis-infected BALB/c mice reacted only to peptides from Ag85A. In contrast, spleen cells from both mouse strains produced elevated levels of IL-2 and IFN-gamma following vaccination with Ag85A, Ag85B, and Ag85C DNA in response to peptides of the three Ag85 proteins, and the epitope repertoire was broader than in infected mice. Despite pronounced sequence homology, a number of immunodominant regions contained component specific epitopes. Thus, BALB/c mice vaccinated with all three Ag85 genes reacted against the same amino acid region, 101 to 120, that was also immunodominant for Ag85A in M. bovis BCG-vaccinated and tuberculosis-infected H-2(d) haplotype mice, but responses were completely component specific. In C57BL/6 mice, a cross-reactive T-cell response was detected against two carboxy-terminal peptides spanning amino acids 241 to 260 and 261 to 280 of Ag85A and Ag85B. These regions were not recognized at all in C57BL/6 mice vaccinated with Ag85C DNA. Our results underline the need for comparative analysis of all three Ag85 components in future vaccination studies.  (+info)

Enhanced immunogenicity to Mycobacterium tuberculosis by vaccination with an alphavirus plasmid replicon expressing antigen 85A. (6/350)

The immunogenicity of a plasmid DNA vaccine incorporating Sindbis virus RNA replicase functions (pSINCP) and expressing antigen 85A (Ag85A) from Mycobacterium tuberculosis was compared with a conventional plasmid DNA vector encoding Ag85A. pSINCP-85A was highly immunogenic in mice and gave enhanced long-term protection against M. tuberculosis compared with the conventional vector.  (+info)

Cutting edge: Mycobacterium tuberculosis blocks Ca2+ signaling and phagosome maturation in human macrophages via specific inhibition of sphingosine kinase. (7/350)

One-third of the world's population is infected with Mycobacterium tuberculosis (Mtb), and three million people die of tuberculosis each year. Following its ingestion by macrophages (MPs), Mtb inhibits the maturation of its phagosome, preventing progression to a bactericidal phagolysosome. Phagocytosis of Mtb is uncoupled from the elevation in MP cytosolic Ca(2+) that normally accompanies microbial ingestion, resulting in inhibition of phagosome-lysosome fusion and increased intracellular viability. This study demonstrates that the mechanism responsible for this failure of Ca(2+)-dependent phagosome maturation involves mycobacterial inhibition of MP sphingosine kinase. Thus, inhibition of sphingosine kinase directly contributes to survival of Mtb within human MPs and represents a novel molecular mechanism of pathogenesis.  (+info)

The Apa protein of Mycobacterium tuberculosis stimulates gamma interferon-secreting CD4+ and CD8+ T cells from purified protein derivative-positive individuals and affords protection in a guinea pig model. (8/350)

The search to identify Mycobacterium tuberculosis antigens capable of conferring protective immunity against tuberculosis has received a boost owing to the resurgence of tuberculosis over the past two decades. It has long been recognized that lymphoid cells are required for protection against M. tuberculosis. While traditionally the CD4(+) populations of T cells were believed to predominantly serve this protective function, a pivotal role for CD8(+) T cells in this task has been increasingly appreciated. We show that the 50- to 55-kDa Apa protein, specified by the Rv1860 gene of M. tuberculosis, can elicit both lymphoproliferative response and gamma interferon (IFN-gamma) production from peripheral blood mononuclear cells (PBMC) of purified protein derivative (PPD)-positive individuals, with significant differences recorded in the levels of responsiveness between PPD-positive healthy controls and pulmonary tuberculosis patients. Flow cytometric analysis of whole blood stimulated with the recombinant Apa protein revealed a sizeable proportion of CD8(+) T cells in addition to CD4(+) T cells contributing to IFN-gamma secretion. PBMC responding to the Apa protein produced no interleukin-4, revealing a Th1 phenotype. A DNA vaccine and a poxvirus recombinant expressing the Apa protein were constructed and tested for their ability to protect immunized guinea pigs against a challenge dose of virulent M. tuberculosis. Although the DNA vaccine afforded little protection, the poxvirus recombinant boost after DNA vaccine priming conferred a significant level of protective immunity, bringing about a considerable reduction in mycobacterial counts from the challenge bacilli in spleens of immunized guinea pigs, a result comparable to that achieved by BCG vaccination.  (+info)

A tuberculosis vaccine, also known as the BCG (Bacillus Calmette-Guérin) vaccine, is a type of immunization used to prevent tuberculosis (TB), a bacterial infection caused by Mycobacterium tuberculosis. The BCG vaccine contains a weakened strain of the bacteria that causes TB in cattle.

The BCG vaccine works by stimulating an immune response in the body, which helps to protect against severe forms of TB, such as TB meningitis and TB in children. However, it is not very effective at preventing pulmonary TB (TB that affects the lungs) in adults.

The BCG vaccine is not routinely recommended for use in the United States due to the low risk of TB infection in the general population. However, it may be given to people who are at high risk of exposure to TB, such as healthcare workers, laboratory personnel, and people traveling to countries with high rates of TB.

It is important to note that the BCG vaccine does not provide complete protection against TB and that other measures, such as testing and treatment for latent TB infection, are also important for controlling the spread of this disease.

Tuberculosis (TB) is a chronic infectious disease caused by the bacterium Mycobacterium tuberculosis. It primarily affects the lungs but can also involve other organs and tissues in the body. The infection is usually spread through the air when an infected person coughs, sneezes, or talks.

The symptoms of pulmonary TB include persistent cough, chest pain, coughing up blood, fatigue, fever, night sweats, and weight loss. Diagnosis typically involves a combination of medical history, physical examination, chest X-ray, and microbiological tests such as sputum smear microscopy and culture. In some cases, molecular tests like polymerase chain reaction (PCR) may be used for rapid diagnosis.

Treatment usually consists of a standard six-month course of multiple antibiotics, including isoniazid, rifampin, ethambutol, and pyrazinamide. In some cases, longer treatment durations or different drug regimens might be necessary due to drug resistance or other factors. Preventive measures include vaccination with the Bacillus Calmette-Guérin (BCG) vaccine and early detection and treatment of infected individuals to prevent transmission.

BCG (Bacillus Calmette-Guérin) vaccine is a type of immunization used primarily to prevent tuberculosis (TB). It contains a live but weakened strain of Mycobacterium bovis, which is related to the bacterium that causes TB in humans (Mycobacterium tuberculosis).

The BCG vaccine works by stimulating an immune response in the body, enabling it to better resist infection with TB bacteria if exposed in the future. It is often given to infants and children in countries where TB is common, and its use varies depending on the national immunization policies. The protection offered by the BCG vaccine is moderate and may not last for a very long time.

In addition to its use against TB, the BCG vaccine has also been investigated for its potential therapeutic role in treating bladder cancer and some other types of cancer. The mechanism of action in these cases is thought to be related to the vaccine's ability to stimulate an immune response against abnormal cells.

Pulmonary tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium tuberculosis. It primarily affects the lungs and can spread to other parts of the body through the bloodstream or lymphatic system. The infection typically enters the body when a person inhales droplets containing the bacteria, which are released into the air when an infected person coughs, sneezes, or talks.

The symptoms of pulmonary TB can vary but often include:

* Persistent cough that lasts for more than three weeks and may produce phlegm or blood-tinged sputum
* Chest pain or discomfort, particularly when breathing deeply or coughing
* Fatigue and weakness
* Unexplained weight loss
* Fever and night sweats
* Loss of appetite

Pulmonary TB can cause serious complications if left untreated, including damage to the lungs, respiratory failure, and spread of the infection to other parts of the body. Treatment typically involves a course of antibiotics that can last several months, and it is essential for patients to complete the full treatment regimen to ensure that the infection is fully eradicated.

Preventive measures include vaccination with the Bacillus Calmette-Guérin (BCG) vaccine, which can provide some protection against severe forms of TB in children, and measures to prevent the spread of the disease, such as covering the mouth and nose when coughing or sneezing, wearing a mask in public places, and avoiding close contact with people who have active TB.

'Mycobacterium tuberculosis' is a species of slow-growing, aerobic, gram-positive bacteria that demonstrates acid-fastness. It is the primary causative agent of tuberculosis (TB) in humans. This bacterium has a complex cell wall rich in lipids, including mycolic acids, which provides a hydrophobic barrier and makes it resistant to many conventional antibiotics. The ability of M. tuberculosis to survive within host macrophages and resist the immune response contributes to its pathogenicity and the difficulty in treating TB infections.

M. tuberculosis is typically transmitted through inhalation of infectious droplets containing the bacteria, which primarily targets the lungs but can spread to other parts of the body (extrapulmonary TB). The infection may result in a spectrum of clinical manifestations, ranging from latent TB infection (LTBI) to active disease. LTBI represents a dormant state where individuals are infected with M. tuberculosis but do not show symptoms and cannot transmit the bacteria. However, they remain at risk of developing active TB throughout their lifetime, especially if their immune system becomes compromised.

Effective prevention and control strategies for TB rely on early detection, treatment, and public health interventions to limit transmission. The current first-line treatments for drug-susceptible TB include a combination of isoniazid, rifampin, ethambutol, and pyrazinamide for at least six months. Multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of M. tuberculosis present significant challenges in TB control and require more complex treatment regimens.

"Mycobacterium bovis" is a species of slow-growing, aerobic, gram-positive bacteria in the family Mycobacteriaceae. It is the causative agent of tuberculosis in cattle and other animals, and can also cause tuberculosis in humans, particularly in those who come into contact with infected animals or consume unpasteurized dairy products from infected cows. The bacteria are resistant to many common disinfectants and survive for long periods in a dormant state, making them difficult to eradicate from the environment. "Mycobacterium bovis" is closely related to "Mycobacterium tuberculosis," the bacterium that causes tuberculosis in humans, and both species share many genetic and biochemical characteristics.

A vaccine is a biological preparation that provides active acquired immunity to a particular infectious disease. It typically contains an agent that resembles the disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it encounters in the future.

Vaccines can be prophylactic (to prevent or ameliorate the effects of a future infection by a natural or "wild" pathogen), or therapeutic (to fight disease that is already present). The administration of vaccines is called vaccination. Vaccinations are generally administered through needle injections, but can also be administered by mouth or sprayed into the nose.

The term "vaccine" comes from Edward Jenner's 1796 use of cowpox to create immunity to smallpox. The first successful vaccine was developed in 1796 by Edward Jenner, who showed that milkmaids who had contracted cowpox did not get smallpox. He reasoned that exposure to cowpox protected against smallpox and tested his theory by injecting a boy with pus from a cowpox sore and then exposing him to smallpox, which the boy did not contract. The word "vaccine" is derived from Variolae vaccinae (smallpox of the cow), the term devised by Jenner to denote cowpox. He used it in 1798 during a conversation with a fellow physician and later in the title of his 1801 Inquiry.

Synthetic vaccines are artificially produced, designed to stimulate an immune response and provide protection against specific diseases. Unlike traditional vaccines that are derived from weakened or killed pathogens, synthetic vaccines are created using synthetic components, such as synthesized viral proteins, DNA, or RNA. These components mimic the disease-causing agent and trigger an immune response without causing the actual disease. The use of synthetic vaccines offers advantages in terms of safety, consistency, and scalability in production, making them valuable tools for preventing infectious diseases.

Vaccination is a simple, safe, and effective way to protect people against harmful diseases, before they come into contact with them. It uses your body's natural defenses to build protection to specific infections and makes your immune system stronger.

A vaccination usually contains a small, harmless piece of a virus or bacteria (or toxins produced by these germs) that has been made inactive or weakened so it won't cause the disease itself. This piece of the germ is known as an antigen. When the vaccine is introduced into the body, the immune system recognizes the antigen as foreign and produces antibodies to fight it.

If a person then comes into contact with the actual disease-causing germ, their immune system will recognize it and immediately produce antibodies to destroy it. The person is therefore protected against that disease. This is known as active immunity.

Vaccinations are important for both individual and public health. They prevent the spread of contagious diseases and protect vulnerable members of the population, such as young children, the elderly, and people with weakened immune systems who cannot be vaccinated or for whom vaccination is not effective.

Bacterial vaccines are types of vaccines that are created using bacteria or parts of bacteria as the immunogen, which is the substance that triggers an immune response in the body. The purpose of a bacterial vaccine is to stimulate the immune system to develop protection against specific bacterial infections.

There are several types of bacterial vaccines, including:

1. Inactivated or killed whole-cell vaccines: These vaccines contain entire bacteria that have been killed or inactivated through various methods, such as heat or chemicals. The bacteria can no longer cause disease, but they still retain the ability to stimulate an immune response.
2. Subunit, protein, or polysaccharide vaccines: These vaccines use specific components of the bacterium, such as proteins or polysaccharides, that are known to trigger an immune response. By using only these components, the vaccine can avoid using the entire bacterium, which may reduce the risk of adverse reactions.
3. Live attenuated vaccines: These vaccines contain live bacteria that have been weakened or attenuated so that they cannot cause disease but still retain the ability to stimulate an immune response. This type of vaccine can provide long-lasting immunity, but it may not be suitable for people with weakened immune systems.

Bacterial vaccines are essential tools in preventing and controlling bacterial infections, reducing the burden of diseases such as tuberculosis, pneumococcal disease, meningococcal disease, and Haemophilus influenzae type b (Hib) disease. They work by exposing the immune system to a harmless form of the bacteria or its components, which triggers the production of antibodies and memory cells that can recognize and fight off future infections with that same bacterium.

It's important to note that while vaccines are generally safe and effective, they may cause mild side effects such as pain, redness, or swelling at the injection site, fever, or fatigue. Serious side effects are rare but can occur, so it's essential to consult with a healthcare provider before receiving any vaccine.

Bacterial antigens are substances found on the surface or produced by bacteria that can stimulate an immune response in a host organism. These antigens can be proteins, polysaccharides, teichoic acids, lipopolysaccharides, or other molecules that are recognized as foreign by the host's immune system.

When a bacterial antigen is encountered by the host's immune system, it triggers a series of responses aimed at eliminating the bacteria and preventing infection. The host's immune system recognizes the antigen as foreign through the use of specialized receptors called pattern recognition receptors (PRRs), which are found on various immune cells such as macrophages, dendritic cells, and neutrophils.

Once a bacterial antigen is recognized by the host's immune system, it can stimulate both the innate and adaptive immune responses. The innate immune response involves the activation of inflammatory pathways, the recruitment of immune cells to the site of infection, and the production of antimicrobial peptides.

The adaptive immune response, on the other hand, involves the activation of T cells and B cells, which are specific to the bacterial antigen. These cells can recognize and remember the antigen, allowing for a more rapid and effective response upon subsequent exposures.

Bacterial antigens are important in the development of vaccines, as they can be used to stimulate an immune response without causing disease. By identifying specific bacterial antigens that are associated with virulence or pathogenicity, researchers can develop vaccines that target these antigens and provide protection against infection.

Inactivated vaccines, also known as killed or non-live vaccines, are created by using a version of the virus or bacteria that has been grown in a laboratory and then killed or inactivated with chemicals, heat, or radiation. This process renders the organism unable to cause disease, but still capable of stimulating an immune response when introduced into the body.

Inactivated vaccines are generally considered safer than live attenuated vaccines since they cannot revert back to a virulent form and cause illness. However, they may require multiple doses or booster shots to maintain immunity because the immune response generated by inactivated vaccines is not as robust as that produced by live vaccines. Examples of inactivated vaccines include those for hepatitis A, rabies, and influenza (inactivated flu vaccine).

Bovine tuberculosis (BTB) is a chronic infectious disease caused by the bacterium Mycobacterium bovis. It primarily affects cattle but can also spread to other mammals including humans, causing a similar disease known as zoonotic tuberculosis. The infection in animals typically occurs through inhalation of infectious droplets or ingestion of contaminated feed and water.

In cattle, the disease often affects the respiratory system, leading to symptoms such as chronic coughing, weight loss, and difficulty breathing. However, it can also affect other organs, including the intestines, lymph nodes, and mammary glands. Diagnosis of BTB typically involves a combination of clinical signs, laboratory tests, and epidemiological data.

Control measures for BTB include regular testing and culling of infected animals, movement restrictions, and vaccination of susceptible populations. In many countries, BTB is a notifiable disease, meaning that cases must be reported to the authorities. Proper cooking and pasteurization of dairy products can help prevent transmission to humans.

A viral vaccine is a biological preparation that introduces your body to a specific virus in a way that helps your immune system build up protection against the virus without causing the illness. Viral vaccines can be made from weakened or inactivated forms of the virus, or parts of the virus such as proteins or sugars. Once introduced to the body, the immune system recognizes the virus as foreign and produces an immune response, including the production of antibodies. These antibodies remain in the body and provide immunity against future infection with that specific virus.

Viral vaccines are important tools for preventing infectious diseases caused by viruses, such as influenza, measles, mumps, rubella, polio, hepatitis A and B, rabies, rotavirus, chickenpox, shingles, and some types of cancer. Vaccination programs have led to the control or elimination of many infectious diseases that were once common.

It's important to note that viral vaccines are not effective against bacterial infections, and separate vaccines must be developed for each type of virus. Additionally, because viruses can mutate over time, it is necessary to update some viral vaccines periodically to ensure continued protection.

Secondary immunization, also known as "anamnestic response" or "booster," refers to the enhanced immune response that occurs upon re-exposure to an antigen, having previously been immunized or infected with the same pathogen. This response is characterized by a more rapid and robust production of antibodies and memory cells compared to the primary immune response. The secondary immunization aims to maintain long-term immunity against infectious diseases and improve vaccine effectiveness. It usually involves administering additional doses of a vaccine or booster shots after the initial series of immunizations, which helps reinforce the immune system's ability to recognize and combat specific pathogens.

I could not find a specific medical definition for "Vaccines, DNA." However, I can provide you with some information about DNA vaccines.

DNA vaccines are a type of vaccine that uses genetically engineered DNA to stimulate an immune response in the body. They work by introducing a small piece of DNA into the body that contains the genetic code for a specific antigen (a substance that triggers an immune response). The cells of the body then use this DNA to produce the antigen, which prompts the immune system to recognize and attack it.

DNA vaccines have several advantages over traditional vaccines. They are relatively easy to produce, can be stored at room temperature, and can be designed to protect against a wide range of diseases. Additionally, because they use DNA to stimulate an immune response, DNA vaccines do not require the growth and culture of viruses or bacteria, which can make them safer than traditional vaccines.

DNA vaccines are still in the experimental stages, and more research is needed to determine their safety and effectiveness. However, they have shown promise in animal studies and are being investigated as a potential tool for preventing a variety of infectious diseases, including influenza, HIV, and cancer.

A tuberculin test is a medical procedure used to determine if someone has developed an immune response to the bacterium that causes tuberculosis (TB), Mycobacterium tuberculosis. The test involves injecting a small amount of purified protein derivative (PPD) from the TB bacteria under the skin, usually on the forearm. After 48-72 hours, the area is examined for signs of a reaction, such as swelling, redness, or hardness. A positive result suggests that the person has been infected with TB at some point in the past, although it does not necessarily mean that they have active TB disease. However, individuals who have a positive tuberculin test should be evaluated further to determine if they need treatment for latent TB infection or active TB disease.

Attenuated vaccines consist of live microorganisms that have been weakened (attenuated) through various laboratory processes so they do not cause disease in the majority of recipients but still stimulate an immune response. The purpose of attenuation is to reduce the virulence or replication capacity of the pathogen while keeping it alive, allowing it to retain its antigenic properties and induce a strong and protective immune response.

Examples of attenuated vaccines include:

1. Sabin oral poliovirus vaccine (OPV): This vaccine uses live but weakened polioviruses to protect against all three strains of the disease-causing poliovirus. The weakened viruses replicate in the intestine and induce an immune response, which provides both humoral (antibody) and cell-mediated immunity.
2. Measles, mumps, and rubella (MMR) vaccine: This combination vaccine contains live attenuated measles, mumps, and rubella viruses. It is given to protect against these three diseases and prevent their spread in the population.
3. Varicella (chickenpox) vaccine: This vaccine uses a weakened form of the varicella-zoster virus, which causes chickenpox. By introducing this attenuated virus into the body, it stimulates an immune response that protects against future infection with the wild-type virus.
4. Yellow fever vaccine: This live attenuated vaccine is used to prevent yellow fever, a viral disease transmitted by mosquitoes in tropical and subtropical regions of Africa and South America. The vaccine contains a weakened form of the yellow fever virus that cannot cause the disease but still induces an immune response.
5. Bacillus Calmette-Guérin (BCG) vaccine: This live attenuated vaccine is used to protect against tuberculosis (TB). It contains a weakened strain of Mycobacterium bovis, which does not cause TB in humans but stimulates an immune response that provides some protection against the disease.

Attenuated vaccines are generally effective at inducing long-lasting immunity and can provide robust protection against targeted diseases. However, they may pose a risk for individuals with weakened immune systems, as the attenuated viruses or bacteria could potentially cause illness in these individuals. Therefore, it is essential to consider an individual's health status before administering live attenuated vaccines.

Combined vaccines are defined in medical terms as vaccines that contain two or more antigens from different diseases, which are given to provide protection against multiple diseases at the same time. This approach reduces the number of injections required and simplifies the immunization schedule, especially during early childhood. Examples of combined vaccines include:

1. DTaP-Hib-IPV (e.g., Pentacel): A vaccine that combines diphtheria, tetanus, pertussis (whooping cough), Haemophilus influenzae type b (Hib) disease, and poliovirus components in one injection to protect against these five diseases.
2. MMRV (e.g., ProQuad): A vaccine that combines measles, mumps, rubella, and varicella (chickenpox) antigens in a single injection to provide immunity against all four diseases.
3. HepA-HepB (e.g., Twinrix): A vaccine that combines hepatitis A and hepatitis B antigens in one injection, providing protection against both types of hepatitis.
4. MenACWY-TT (e.g., MenQuadfi): A vaccine that combines four serogroups of meningococcal bacteria (A, C, W, Y) with tetanus toxoid as a carrier protein in one injection for the prevention of invasive meningococcal disease caused by these serogroups.
5. PCV13-PPSV23 (e.g., Vaxneuvance): A vaccine that combines 13 pneumococcal serotypes with PPSV23, providing protection against a broader range of pneumococcal diseases in adults aged 18 years and older.

Combined vaccines have been thoroughly tested for safety and efficacy to ensure they provide a strong immune response and an acceptable safety profile. They are essential tools in preventing various infectious diseases and improving overall public health.

Multidrug-resistant tuberculosis (MDR-TB) is a form of tuberculosis (TB) infection caused by bacteria that are resistant to at least two of the first-line anti-TB drugs, isoniazid and rifampin. This makes MDR-TB more difficult and expensive to treat, requiring longer treatment durations and the use of second-line medications, which can have more severe side effects.

MDR-TB can occur when there are errors in prescribing or taking anti-TB drugs, or when people with TB do not complete their full course of treatment. It is a significant global health concern, particularly in low- and middle-income countries where TB is more prevalent and resources for diagnosis and treatment may be limited.

MDR-TB can spread from person to person through the air when someone with the infection coughs, speaks, or sneezes. People at higher risk of contracting MDR-TB include those who have been in close contact with someone with MDR-TB, people with weakened immune systems, and healthcare workers who treat TB patients.

Preventing the spread of MDR-TB involves early detection and prompt treatment, as well as infection control measures such as wearing masks, improving ventilation, and separating infected individuals from others. It is also important to ensure that anti-TB drugs are used correctly and that patients complete their full course of treatment to prevent the development of drug-resistant strains.

"Mycobacterium" is a genus of gram-positive, aerobic, rod-shaped bacteria that are characterized by their complex cell walls containing large amounts of lipids. This genus includes several species that are significant in human and animal health, most notably Mycobacterium tuberculosis, which causes tuberculosis, and Mycobacterium leprae, which causes leprosy. Other species of Mycobacterium can cause various diseases in humans, including skin and soft tissue infections, lung infections, and disseminated disease in immunocompromised individuals. These bacteria are often resistant to common disinfectants and antibiotics, making them difficult to treat.

Immunologic adjuvants are substances that are added to a vaccine to enhance the body's immune response to the antigens contained in the vaccine. They work by stimulating the immune system and promoting the production of antibodies and activating immune cells, such as T-cells and macrophages, which help to provide a stronger and more sustained immune response to the vaccine.

Immunologic adjuvants can be derived from various sources, including bacteria, viruses, and chemicals. Some common examples include aluminum salts (alum), oil-in-water emulsions (such as MF59), and bacterial components (such as lipopolysaccharide or LPS).

The use of immunologic adjuvants in vaccines can help to improve the efficacy of the vaccine, particularly for vaccines that contain weak or poorly immunogenic antigens. They can also help to reduce the amount of antigen needed in a vaccine, which can be beneficial for vaccines that are difficult or expensive to produce.

It's important to note that while adjuvants can enhance the immune response to a vaccine, they can also increase the risk of adverse reactions, such as inflammation and pain at the injection site. Therefore, the use of immunologic adjuvants must be carefully balanced against their potential benefits and risks.

An AIDS vaccine is a type of preventive vaccine that aims to stimulate the immune system to produce an effective response against the human immunodeficiency virus (HIV), which causes acquired immunodeficiency syndrome (AIDS). The goal of an AIDS vaccine is to induce the production of immune cells and proteins that can recognize and eliminate HIV-infected cells, thereby preventing the establishment of a persistent infection.

Despite decades of research, there is still no licensed AIDS vaccine available. This is due in part to the unique challenges posed by HIV, which has a high mutation rate and can rapidly evolve to evade the immune system's defenses. However, several promising vaccine candidates are currently being tested in clinical trials around the world, and researchers continue to explore new approaches and strategies for developing an effective AIDS vaccine.

Bacterial proteins are a type of protein that are produced by bacteria as part of their structural or functional components. These proteins can be involved in various cellular processes, such as metabolism, DNA replication, transcription, and translation. They can also play a role in bacterial pathogenesis, helping the bacteria to evade the host's immune system, acquire nutrients, and multiply within the host.

Bacterial proteins can be classified into different categories based on their function, such as:

1. Enzymes: Proteins that catalyze chemical reactions in the bacterial cell.
2. Structural proteins: Proteins that provide structural support and maintain the shape of the bacterial cell.
3. Signaling proteins: Proteins that help bacteria to communicate with each other and coordinate their behavior.
4. Transport proteins: Proteins that facilitate the movement of molecules across the bacterial cell membrane.
5. Toxins: Proteins that are produced by pathogenic bacteria to damage host cells and promote infection.
6. Surface proteins: Proteins that are located on the surface of the bacterial cell and interact with the environment or host cells.

Understanding the structure and function of bacterial proteins is important for developing new antibiotics, vaccines, and other therapeutic strategies to combat bacterial infections.

Interferon-gamma (IFN-γ) is a soluble cytokine that is primarily produced by the activation of natural killer (NK) cells and T lymphocytes, especially CD4+ Th1 cells and CD8+ cytotoxic T cells. It plays a crucial role in the regulation of the immune response against viral and intracellular bacterial infections, as well as tumor cells. IFN-γ has several functions, including activating macrophages to enhance their microbicidal activity, increasing the presentation of major histocompatibility complex (MHC) class I and II molecules on antigen-presenting cells, stimulating the proliferation and differentiation of T cells and NK cells, and inducing the production of other cytokines and chemokines. Additionally, IFN-γ has direct antiproliferative effects on certain types of tumor cells and can enhance the cytotoxic activity of immune cells against infected or malignant cells.

A subunit vaccine is a type of vaccine that contains a specific piece or component of the microorganism (such as a protein, sugar, or part of the bacterial outer membrane), instead of containing the entire organism. This piece of the microorganism is known as an antigen, and it stimulates an immune response in the body, allowing the development of immunity against the targeted infection without introducing the risk of disease associated with live vaccines.

Subunit vaccines offer several advantages over other types of vaccines. They are generally safer because they do not contain live or weakened microorganisms, making them suitable for individuals with weakened immune systems or specific medical conditions that prevent them from receiving live vaccines. Additionally, subunit vaccines can be designed to focus on the most immunogenic components of a pathogen, potentially leading to stronger and more targeted immune responses.

Examples of subunit vaccines include the Hepatitis B vaccine, which contains a viral protein, and the Haemophilus influenzae type b (Hib) vaccine, which uses pieces of the bacterial polysaccharide capsule. These vaccines have been crucial in preventing serious infectious diseases and reducing associated complications worldwide.

Conjugate vaccines are a type of vaccine that combines a part of a bacterium with a protein or other substance to boost the body's immune response to the bacteria. The bacterial component is usually a polysaccharide, which is a long chain of sugars that makes up part of the bacterial cell wall.

By itself, a polysaccharide is not very immunogenic, meaning it does not stimulate a strong immune response. However, when it is conjugated or linked to a protein or other carrier molecule, it becomes much more immunogenic and can elicit a stronger and longer-lasting immune response.

Conjugate vaccines are particularly effective in protecting against bacterial infections that affect young children, such as Haemophilus influenzae type b (Hib) and pneumococcal disease. These vaccines have been instrumental in reducing the incidence of these diseases and their associated complications, such as meningitis and pneumonia.

Overall, conjugate vaccines work by mimicking a natural infection and stimulating the immune system to produce antibodies that can protect against future infections with the same bacterium. By combining a weakly immunogenic polysaccharide with a protein carrier, these vaccines can elicit a stronger and more effective immune response, providing long-lasting protection against bacterial infections.

Miliary tuberculosis is a disseminated form of tuberculosis (TB), a bacterial infection caused by Mycobacterium tuberculosis. The term "miliary" refers to the tiny millet-like size (2-5 microns in diameter) of the TB foci observed in the lungs or other organs during autopsy or on imaging studies. In military tuberculosis, these small granules are widespread throughout the body, affecting multiple organs such as the lungs, liver, spleen, bones, and brain. It can occur in people with weakened immune systems, including those with HIV/AIDS, or in individuals who have recently been infected with TB bacteria. Symptoms may include fever, night sweats, weight loss, fatigue, and cough. Early diagnosis and treatment are crucial to prevent severe complications and improve outcomes.

Acyltransferases are a group of enzymes that catalyze the transfer of an acyl group (a functional group consisting of a carbon atom double-bonded to an oxygen atom and single-bonded to a hydrogen atom) from one molecule to another. This transfer involves the formation of an ester bond between the acyl group donor and the acyl group acceptor.

Acyltransferases play important roles in various biological processes, including the biosynthesis of lipids, fatty acids, and other metabolites. They are also involved in the detoxification of xenobiotics (foreign substances) by catalyzing the addition of an acyl group to these compounds, making them more water-soluble and easier to excrete from the body.

Examples of acyltransferases include serine palmitoyltransferase, which is involved in the biosynthesis of sphingolipids, and cholesteryl ester transfer protein (CETP), which facilitates the transfer of cholesteryl esters between lipoproteins.

Acyltransferases are classified based on the type of acyl group they transfer and the nature of the acyl group donor and acceptor molecules. They can be further categorized into subclasses based on their sequence similarities, three-dimensional structures, and evolutionary relationships.

Cellular immunity, also known as cell-mediated immunity, is a type of immune response that involves the activation of immune cells, such as T lymphocytes (T cells), to protect the body against infected or damaged cells. This form of immunity is important for fighting off infections caused by viruses and intracellular bacteria, as well as for recognizing and destroying cancer cells.

Cellular immunity involves a complex series of interactions between various immune cells and molecules. When a pathogen infects a cell, the infected cell displays pieces of the pathogen on its surface in a process called antigen presentation. This attracts T cells, which recognize the antigens and become activated. Activated T cells then release cytokines, chemicals that help coordinate the immune response, and can directly attack and kill infected cells or help activate other immune cells to do so.

Cellular immunity is an important component of the adaptive immune system, which is able to learn and remember specific pathogens in order to mount a faster and more effective response upon subsequent exposure. This form of immunity is also critical for the rejection of transplanted organs, as the immune system recognizes the transplanted tissue as foreign and attacks it.

Isoniazid is an antimicrobial medication used for the prevention and treatment of tuberculosis (TB). It is a first-line medication, often used in combination with other TB drugs, to kill the Mycobacterium tuberculosis bacteria that cause TB. Isoniazid works by inhibiting the synthesis of mycolic acids, which are essential components of the bacterial cell wall. This leads to bacterial death and helps to control the spread of TB.

Isoniazid is available in various forms, including tablets, capsules, and liquid solutions. It can be taken orally or given by injection. The medication is generally well-tolerated, but it can cause side effects such as peripheral neuropathy, hepatitis, and skin rashes. Regular monitoring of liver function tests and supplementation with pyridoxine (vitamin B6) may be necessary to prevent or manage these side effects.

It is important to note that Isoniazid is not effective against drug-resistant strains of TB, and its use should be guided by the results of drug susceptibility testing. Additionally, it is essential to complete the full course of treatment as prescribed to ensure the successful eradication of the bacteria and prevent the development of drug-resistant strains.

CD4-positive T-lymphocytes, also known as CD4+ T cells or helper T cells, are a type of white blood cell that plays a crucial role in the immune response. They express the CD4 receptor on their surface and help coordinate the immune system's response to infectious agents such as viruses and bacteria.

CD4+ T cells recognize and bind to specific antigens presented by antigen-presenting cells, such as dendritic cells or macrophages. Once activated, they can differentiate into various subsets of effector cells, including Th1, Th2, Th17, and Treg cells, each with distinct functions in the immune response.

CD4+ T cells are particularly important in the immune response to HIV (human immunodeficiency virus), which targets and destroys these cells, leading to a weakened immune system and increased susceptibility to opportunistic infections. The number of CD4+ T cells is often used as a marker of disease progression in HIV infection, with lower counts indicating more advanced disease.

A lung is a pair of spongy, elastic organs in the chest that work together to enable breathing. They are responsible for taking in oxygen and expelling carbon dioxide through the process of respiration. The left lung has two lobes, while the right lung has three lobes. The lungs are protected by the ribcage and are covered by a double-layered membrane called the pleura. The trachea divides into two bronchi, which further divide into smaller bronchioles, leading to millions of tiny air sacs called alveoli, where the exchange of gases occurs.

Latent Tuberculosis (TB) infection is defined as a state of persistent immune response to stimulation by Mycobacterium tuberculosis without evidence of clinically manifest active TB disease. The individuals with latent TB infection do not feel ill and are not infectious. However, they may develop active TB disease later in their lives, typically within the first 2 years after infection. It's estimated that about 5-10% of people with latent TB infection will develop active TB disease during their lifetime. The risk is higher in people who have weakened immune systems due to HIV infection, malnutrition, aging, or use of immunosuppressive medications. Diagnosis of latent TB infection is typically made through a tuberculin skin test or an interferon-gamma release assay (IGRA). Treatment of latent TB infection can reduce the risk of developing active TB disease.

Tuberculosis (TB) of the lymph node, also known as scrofula or tuberculous lymphadenitis, is a specific form of extrapulmonary tuberculosis. It involves the infection and inflammation of the lymph nodes (lymph glands) by the Mycobacterium tuberculosis bacterium. The lymph nodes most commonly affected are the cervical (neck) and supraclavicular (above the collarbone) lymph nodes, but other sites can also be involved.

The infection typically spreads to the lymph nodes through the bloodstream or via nearby infected organs, such as the lungs or intestines. The affected lymph nodes may become enlarged, firm, and tender, forming masses called cold abscesses that can suppurate (form pus) and eventually rupture. In some cases, the lymph nodes may calcify, leaving hard, stone-like deposits.

Diagnosis of tuberculous lymphadenitis often involves a combination of clinical evaluation, imaging studies (such as CT or MRI scans), and microbiological or histopathological examination of tissue samples obtained through fine-needle aspiration biopsy or surgical excision. Treatment typically consists of a standard anti-tuberculosis multi-drug regimen, which may include isoniazid, rifampin, ethambutol, and pyrazinamide for at least six months. Surgical intervention might be necessary in cases with complications or treatment failure.

Malaria vaccines are biological preparations that induce immunity against malaria parasites, thereby preventing or reducing the severity of malaria disease. They typically contain antigens (proteins or other molecules derived from the parasite) that stimulate an immune response in the recipient, enabling their body to recognize and neutralize the pathogen upon exposure.

The most advanced malaria vaccine candidate is RTS,S/AS01 (Mosquirix), which targets the Plasmodium falciparum parasite's circumsporozoite protein (CSP). This vaccine has shown partial protection in clinical trials, reducing the risk of severe malaria and hospitalization in young children by about 30% over four years. However, it does not provide complete immunity, and additional research is ongoing to develop more effective vaccines against malaria.

BALB/c is an inbred strain of laboratory mouse that is widely used in biomedical research. The strain was developed at the Institute of Cancer Research in London by Henry Baldwin and his colleagues in the 1920s, and it has since become one of the most commonly used inbred strains in the world.

BALB/c mice are characterized by their black coat color, which is determined by a recessive allele at the tyrosinase locus. They are also known for their docile and friendly temperament, making them easy to handle and work with in the laboratory.

One of the key features of BALB/c mice that makes them useful for research is their susceptibility to certain types of tumors and immune responses. For example, they are highly susceptible to developing mammary tumors, which can be induced by chemical carcinogens or viral infection. They also have a strong Th2-biased immune response, which makes them useful models for studying allergic diseases and asthma.

BALB/c mice are also commonly used in studies of genetics, neuroscience, behavior, and infectious diseases. Because they are an inbred strain, they have a uniform genetic background, which makes it easier to control for genetic factors in experiments. Additionally, because they have been bred in the laboratory for many generations, they are highly standardized and reproducible, making them ideal subjects for scientific research.

I must clarify that the term "Guinea Pigs" is not typically used in medical definitions. However, in colloquial or informal language, it may refer to people who are used as the first to try out a new medical treatment or drug. This is known as being a "test subject" or "in a clinical trial."

In the field of scientific research, particularly in studies involving animals, guinea pigs are small rodents that are often used as experimental subjects due to their size, cost-effectiveness, and ease of handling. They are not actually pigs from Guinea, despite their name's origins being unclear. However, they do not exactly fit the description of being used in human medical experiments.

Osteoarticular tuberculosis is a form of extrapulmonary tuberculosis (TB) that involves the bones and joints. It is caused by the bacterium Mycobacterium tuberculosis. The infection can spread to the bones and joints through the bloodstream or from nearby infected organs, such as the lungs.

The most commonly affected sites are the spine (Pott's disease), hip, knee, wrist, and small bones of the hands and feet. Symptoms may include pain, swelling, stiffness, and decreased range of motion in the affected joint or bone. In some cases, the infection can lead to deformity, chronic disability, or even death if left untreated.

Diagnosis typically involves a combination of medical history, physical examination, imaging studies (such as X-rays, CT scans, or MRI), and laboratory tests (such as blood tests, sputum cultures, or biopsy). Treatment usually consists of a long course of antibiotics (usually for at least six months) to kill the bacteria. Surgery may also be necessary in some cases to remove infected tissue or stabilize damaged joints.

CD8-positive T-lymphocytes, also known as CD8+ T cells or cytotoxic T cells, are a type of white blood cell that plays a crucial role in the adaptive immune system. They are named after the CD8 molecule found on their surface, which is a protein involved in cell signaling and recognition.

CD8+ T cells are primarily responsible for identifying and destroying virus-infected cells or cancerous cells. When activated, they release cytotoxic granules that contain enzymes capable of inducing apoptosis (programmed cell death) in the target cells. They also produce cytokines such as interferon-gamma, which can help coordinate the immune response and activate other immune cells.

CD8+ T cells are generated in the thymus gland and are a type of T cell, which is a lymphocyte that matures in the thymus and plays a central role in cell-mediated immunity. They recognize and respond to specific antigens presented on the surface of infected or cancerous cells in conjunction with major histocompatibility complex (MHC) class I molecules.

Overall, CD8+ T cells are an essential component of the immune system's defense against viral infections and cancer.

Gastrointestinal tuberculosis (GTB) is a type of tuberculosis that affects the gastrointestinal tract, including the stomach, intestines, and associated organs such as the liver and spleen. It is caused by the bacterium Mycobacterium tuberculosis, which typically infects the lungs (pulmonary TB) but can spread to other parts of the body through the bloodstream or lymphatic system.

In GTB, the bacteria invade the tissues of the gastrointestinal tract and cause inflammation, ulceration, and thickening of the intestinal wall. This can lead to a variety of symptoms, including abdominal pain, diarrhea (which may be bloody), weight loss, fever, and fatigue. GTB can also cause complications such as bowel obstruction, perforation, or fistula formation.

Diagnosis of GTB can be challenging, as the symptoms are non-specific and can mimic those of other gastrointestinal disorders. Diagnostic tests may include endoscopy, biopsy, culture, and molecular testing for the presence of M. tuberculosis. Treatment typically involves a prolonged course of multiple antibiotics, such as isoniazid, rifampin, ethambutol, and pyrazinamide, administered under the guidance of a healthcare provider.

It's worth noting that GTB is relatively rare in developed countries with low rates of tuberculosis, but it is more common in areas where TB is endemic or among populations with weakened immune systems, such as those with HIV/AIDS.

Tuberculosis (TB) of the spine, also known as Pott's disease, is a specific form of extrapulmonary tuberculosis that involves the vertebral column. It is caused by the Mycobacterium tuberculosis bacterium, which primarily affects the lungs but can spread through the bloodstream to other parts of the body, including the spine.

In Pott's disease, the infection leads to the destruction of the spongy bone (vertebral body) and the intervertebral disc space, resulting in vertebral collapse, kyphosis (hunchback deformity), and potential neurological complications due to spinal cord compression. Common symptoms include back pain, stiffness, fever, night sweats, and weight loss. Early diagnosis and treatment with a multidrug antibiotic regimen are crucial to prevent long-term disability and further spread of the infection.

Papillomavirus vaccines are vaccines that have been developed to prevent infection by human papillomaviruses (HPV). HPV is a DNA virus that is capable of infecting the skin and mucous membranes. Certain types of HPV are known to cause cervical cancer, as well as other types of cancer such as anal, penile, vulvar, and oropharyngeal cancers. Other types of HPV can cause genital warts.

There are currently two papillomavirus vaccines that have been approved for use in the United States: Gardasil and Cervarix. Both vaccines protect against the two most common cancer-causing types of HPV (types 16 and 18), which together cause about 70% of cervical cancers. Gardasil also protects against the two most common types of HPV that cause genital warts (types 6 and 11).

Papillomavirus vaccines are given as a series of three shots over a period of six months. They are most effective when given to people before they become sexually active, as this reduces the risk of exposure to HPV. The Centers for Disease Control and Prevention (CDC) recommends that all boys and girls get vaccinated against HPV at age 11 or 12, but the vaccine can be given to people as young as age 9 and as old as age 26.

It is important to note that papillomavirus vaccines do not protect against all types of HPV, and they do not treat existing HPV infections or cervical cancer. They are intended to prevent new HPV infections and the cancers and other diseases that can be caused by HPV.

Cutaneous tuberculosis (CTB) is a rare form of tuberculosis that affects the skin. It is caused by the Mycobacterium tuberculosis complex, including M. tuberculosis, M. bovis, and M. africanum. CTB can occur as a primary infection after direct inoculation of the skin with the bacteria, or it can be secondary to a distant focus of infection such as lung or lymph node TB.

The clinical presentation of CTB is varied and can include papules, nodules, pustules, ulcers, plaques, or scaly lesions. The lesions may be painless or painful, and they can be associated with systemic symptoms such as fever, night sweats, and weight loss.

CTB can be diagnosed through a combination of clinical examination, skin biopsy, culture, and PCR testing. Treatment typically involves a prolonged course of multiple antibiotics, often for six to nine months or more. The most commonly used drugs are isoniazid, rifampin, ethambutol, and pyrazinamide. Surgical excision may be necessary in some cases.

Prevention measures include early detection and treatment of pulmonary TB, BCG vaccination, and avoiding contact with people with active TB.

Meningococcal vaccines are vaccines that protect against Neisseria meningitidis, a type of bacteria that can cause serious infections such as meningitis (inflammation of the lining of the brain and spinal cord) and septicemia (bloodstream infection). There are several types of meningococcal vaccines available, including conjugate vaccines and polysaccharide vaccines. These vaccines work by stimulating the immune system to produce antibodies that can protect against the different serogroups of N. meningitidis, including A, B, C, Y, and W-135. The specific type of vaccine used and the number of doses required may depend on a person's age, health status, and other factors. Meningococcal vaccines are recommended for certain high-risk populations, such as infants, young children, adolescents, and people with certain medical conditions, as well as for travelers to areas where meningococcal disease is common.

Clinical trials are research studies that involve human participants and are designed to evaluate the safety and efficacy of new medical treatments, drugs, devices, or behavioral interventions. The purpose of clinical trials is to determine whether a new intervention is safe, effective, and beneficial for patients, as well as to compare it with currently available treatments. Clinical trials follow a series of phases, each with specific goals and criteria, before a new intervention can be approved by regulatory authorities for widespread use.

Clinical trials are conducted according to a protocol, which is a detailed plan that outlines the study's objectives, design, methodology, statistical analysis, and ethical considerations. The protocol is developed and reviewed by a team of medical experts, statisticians, and ethicists, and it must be approved by an institutional review board (IRB) before the trial can begin.

Participation in clinical trials is voluntary, and participants must provide informed consent before enrolling in the study. Informed consent involves providing potential participants with detailed information about the study's purpose, procedures, risks, benefits, and alternatives, as well as their rights as research subjects. Participants can withdraw from the study at any time without penalty or loss of benefits to which they are entitled.

Clinical trials are essential for advancing medical knowledge and improving patient care. They help researchers identify new treatments, diagnostic tools, and prevention strategies that can benefit patients and improve public health. However, clinical trials also pose potential risks to participants, including adverse effects from experimental interventions, time commitment, and inconvenience. Therefore, it is important for researchers to carefully design and conduct clinical trials to minimize risks and ensure that the benefits outweigh the risks.

Rifampin is an antibiotic medication that belongs to the class of drugs known as rifamycins. It works by inhibiting bacterial DNA-dependent RNA polymerase, thereby preventing bacterial growth and multiplication. Rifampin is used to treat a variety of infections caused by bacteria, including tuberculosis, Haemophilus influenzae, Neisseria meningitidis, and Legionella pneumophila. It is also used to prevent meningococcal disease in people who have been exposed to the bacteria.

Rifampin is available in various forms, including tablets, capsules, and injectable solutions. The medication is usually taken two to four times a day, depending on the type and severity of the infection being treated. Rifampin may be given alone or in combination with other antibiotics.

It is important to note that rifampin can interact with several other medications, including oral contraceptives, anticoagulants, and anti-seizure drugs, among others. Therefore, it is essential to inform your healthcare provider about all the medications you are taking before starting treatment with rifampin.

Rifampin may cause side effects such as nausea, vomiting, diarrhea, dizziness, headache, and changes in the color of urine, tears, sweat, and saliva to a reddish-orange color. These side effects are usually mild and go away on their own. However, if they persist or become bothersome, it is important to consult your healthcare provider.

In summary, rifampin is an antibiotic medication used to treat various bacterial infections and prevent meningococcal disease. It works by inhibiting bacterial DNA-dependent RNA polymerase, preventing bacterial growth and multiplication. Rifampin may interact with several other medications, and it can cause side effects such as nausea, vomiting, diarrhea, dizziness, headache, and changes in the color of body fluids.

C57BL/6 (C57 Black 6) is an inbred strain of laboratory mouse that is widely used in biomedical research. The term "inbred" refers to a strain of animals where matings have been carried out between siblings or other closely related individuals for many generations, resulting in a population that is highly homozygous at most genetic loci.

The C57BL/6 strain was established in 1920 by crossing a female mouse from the dilute brown (DBA) strain with a male mouse from the black strain. The resulting offspring were then interbred for many generations to create the inbred C57BL/6 strain.

C57BL/6 mice are known for their robust health, longevity, and ease of handling, making them a popular choice for researchers. They have been used in a wide range of biomedical research areas, including studies of cancer, immunology, neuroscience, cardiovascular disease, and metabolism.

One of the most notable features of the C57BL/6 strain is its sensitivity to certain genetic modifications, such as the introduction of mutations that lead to obesity or impaired glucose tolerance. This has made it a valuable tool for studying the genetic basis of complex diseases and traits.

Overall, the C57BL/6 inbred mouse strain is an important model organism in biomedical research, providing a valuable resource for understanding the genetic and molecular mechanisms underlying human health and disease.

Sputum is defined as a mixture of saliva and phlegm that is expelled from the respiratory tract during coughing, sneezing or deep breathing. It can be clear, mucoid, or purulent (containing pus) depending on the underlying cause of the respiratory issue. Examination of sputum can help diagnose various respiratory conditions such as infections, inflammation, or other lung diseases.

"Hepatitis B vaccines are vaccines that prevent infection caused by the hepatitis B virus. They work by introducing a small and harmless piece of the virus to your body, which triggers your immune system to produce antibodies to fight off the infection. These antibodies remain in your body and provide protection if you are exposed to the real hepatitis B virus in the future.

The hepatitis B vaccine is typically given as a series of three shots over a six-month period. It is recommended for all infants, children and adolescents who have not previously been vaccinated, as well as for adults who are at increased risk of infection, such as healthcare workers, people who inject drugs, and those with certain medical conditions.

It's important to note that hepatitis B vaccine does not provide protection against other types of viral hepatitis, such as hepatitis A or C."

A measles vaccine is a biological preparation that induces immunity against the measles virus. It contains an attenuated (weakened) strain of the measles virus, which stimulates the immune system to produce antibodies that protect against future infection with the wild-type (disease-causing) virus. Measles vaccines are typically administered in combination with vaccines against mumps and rubella (German measles), forming the MMR vaccine.

The measles vaccine is highly effective, with one or two doses providing immunity in over 95% of people who receive it. It is usually given to children as part of routine childhood immunization programs, with the first dose administered at 12-15 months of age and the second dose at 4-6 years of age.

Measles vaccination has led to a dramatic reduction in the incidence of measles worldwide and is considered one of the greatest public health achievements of the past century. However, despite widespread availability of the vaccine, measles remains a significant cause of morbidity and mortality in some parts of the world, particularly in areas with low vaccination coverage or where access to healthcare is limited.

Pleural Tuberculosis is a form of extrapulmonary tuberculosis (EPTB) that involves the infection and inflammation of the pleura, which are the thin membranes that surround the lungs and line the inside of the chest cavity. This condition is caused by the Mycobacterium tuberculosis bacterium, which can spread through the air when an infected person coughs, sneezes, or talks.

In pleural tuberculosis, the bacteria reach the pleura either through direct extension from a nearby lung infection or via bloodstream dissemination. The infection can cause the pleura to become inflamed and produce excess fluid, leading to pleural effusion. This accumulation of fluid in the pleural space can cause chest pain, coughing, and difficulty breathing.

Diagnosis of pleural tuberculosis typically involves a combination of medical history, physical examination, imaging studies such as chest X-rays or CT scans, and laboratory tests such as acid-fast bacilli (AFB) smear microscopy, culture, and nucleic acid amplification tests (NAATs) to detect the presence of M. tuberculosis in the pleural fluid or tissue samples.

Treatment of pleural tuberculosis typically involves a standard course of anti-tuberculosis therapy (ATT), which includes a combination of multiple antibiotics such as isoniazid, rifampin, ethambutol, and pyrazinamide. The duration of treatment may vary depending on the severity of the infection and the patient's response to therapy. In some cases, surgical intervention may be necessary to drain the pleural effusion or remove the infected pleura.

Extensively Drug-Resistant Tuberculosis (XDR-TB) is a term used to describe a rare, severe form of tuberculosis (TB) that is resistant to the majority of available drugs used to treat TB. This means that the bacteria that cause TB have developed resistance to at least four of the core anti-TB drugs, including isoniazid and rifampin, as well as any fluoroquinolone and at least one of the three injectable second-line drugs (amikacin, capreomycin, or kanamycin).

XDR-TB can be challenging to diagnose and treat due to its resistance to multiple drugs. It is also more likely to cause severe illness, spread from person to person, and result in poor treatment outcomes compared to drug-susceptible TB. XDR-TB is a public health concern, particularly in areas with high rates of TB and limited access to effective treatments.

It's important to note that XDR-TB should not be confused with Multi-Drug Resistant Tuberculosis (MDR-TB), which refers to TB that is resistant to at least isoniazid and rifampin, but not necessarily to the other second-line drugs.

Tuberculosis (TB) is a bacterial infection caused by Mycobacterium tuberculosis. Urogenital tuberculosis (UTB) is a less common form of TB that affects the urinary and genital systems. It occurs when the bacteria spread through the bloodstream from the initial site of infection, usually the lungs, to the kidneys. The infection can then spread to other parts of the urinary system, including the ureters, bladder, and urethra, as well as the genital organs in both men and women.

UTB symptoms may include:
- Persistent dull pain in the lower back or side
- Frequent urination or urgent need to urinate
- Painful urination (dysuria)
- Blood in the urine (hematuria)
- Incontinence
- Sexual dysfunction in men, such as epididymitis or infertility
- Scrotal mass in men
- Amenorrhea or irregular menstruation in women

Diagnosis of UTB typically involves a combination of medical history, physical examination, imaging tests (such as ultrasound, CT scan, or MRI), urine analysis and culture, and sometimes biopsy. Treatment usually consists of a prolonged course of multiple antibiotics to eliminate the infection. Surgery may be required in some cases to repair damaged organs or remove scar tissue.

A Pertussis vaccine is a type of immunization used to protect against pertussis, also known as whooping cough. It contains components that stimulate the immune system to produce antibodies against the bacteria that cause pertussis, Bordetella pertussis. There are two main types of pertussis vaccines: whole-cell pertussis (wP) vaccines and acellular pertussis (aP) vaccines. wP vaccines contain killed whole cells of B. pertussis, while aP vaccines contain specific components of the bacteria, such as pertussis toxin and other antigens. Pertussis vaccines are often combined with diphtheria and tetanus to form combination vaccines, such as DTaP (diphtheria, tetanus, and acellular pertussis) and TdaP (tetanus, diphtheria, and acellular pertussis). These vaccines are typically given to young children as part of their routine immunization schedule.

Meningeal tuberculosis, also known as Tuberculous meningitis, is a severe form of tuberculosis (TB) that affects the meninges, which are the membranes covering the brain and spinal cord. It is caused by the Mycobacterium tuberculosis bacterium, which can spread through the bloodstream from a primary infection site in the lungs or elsewhere in the body.

In meningeal tuberculosis, the bacteria cause inflammation and thickening of the meninges, leading to increased intracranial pressure, cerebral edema, and vasculitis. These conditions can result in various neurological symptoms such as headache, fever, stiff neck, altered mental status, seizures, and focal neurologic deficits. If left untreated, meningeal tuberculosis can lead to severe complications, including brain damage, hydrocephalus, and even death.

Diagnosis of meningeal tuberculosis typically involves a combination of clinical symptoms, cerebrospinal fluid (CSF) analysis, imaging studies, and sometimes molecular or culture-based tests to detect the presence of Mycobacterium tuberculosis in the CSF. Treatment usually involves a prolonged course of antibiotics specifically designed to target TB, such as isoniazid, rifampin, ethambutol, and pyrazinamide, often administered for six to nine months or longer. In some cases, corticosteroids may also be used to reduce inflammation and prevent complications.

Pyrazinamide is an antituberculosis agent, a type of medication used to treat tuberculosis (TB) caused by Mycobacterium tuberculosis. It is an antimicrobial drug that works by inhibiting the growth of the bacterium. Pyrazinamide is often used in combination with other TB drugs such as isoniazid, rifampin, and ethambutol.

The medical definition of Pyrazinamide is: a synthetic antituberculosis agent, C6H5N3O (a pyridine derivative), used in the treatment of tuberculosis, especially in combination with isoniazid and rifampin. It is converted in the body to its active form, pyrazinoic acid, which inhibits the growth of Mycobacterium tuberculosis by interfering with bacterial cell wall synthesis.

It's important to note that Pyrazinamide should be used under the supervision of a healthcare professional and is usually prescribed for several months to ensure complete eradication of the TB bacteria. As with any medication, it can cause side effects, and individuals should report any unusual symptoms to their healthcare provider.

Antitubercular antibiotics are a class of medications specifically used to treat tuberculosis (TB) and other mycobacterial infections. Tuberculosis is caused by the bacterium Mycobacterium tuberculosis, which can affect various organs, primarily the lungs.

There are several antitubercular antibiotics available, with different mechanisms of action that target the unique cell wall structure and metabolism of mycobacteria. Some commonly prescribed antitubercular antibiotics include:

1. Isoniazid (INH): This is a first-line medication for treating TB. It inhibits the synthesis of mycolic acids, a crucial component of the mycobacterial cell wall. Isoniazid can be bactericidal or bacteriostatic depending on the concentration and duration of treatment.
2. Rifampin (RIF): Also known as rifampicin, this antibiotic inhibits bacterial DNA-dependent RNA polymerase, preventing the transcription of genetic information into mRNA. It is a potent bactericidal agent against mycobacteria and is often used in combination with other antitubercular drugs.
3. Ethambutol (EMB): This antibiotic inhibits the synthesis of arabinogalactan and mycolic acids, both essential components of the mycobacterial cell wall. Ethambutol is primarily bacteriostatic but can be bactericidal at higher concentrations.
4. Pyrazinamide (PZA): This medication is active against dormant or slow-growing mycobacteria, making it an essential component of TB treatment regimens. Its mechanism of action involves the inhibition of fatty acid synthesis and the disruption of bacterial membrane potential.
5. Streptomycin: An aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting protein synthesis in mycobacteria. It is primarily used as a second-line treatment for drug-resistant TB.
6. Fluoroquinolones: These are a class of antibiotics that inhibit DNA gyrase and topoisomerase IV, essential enzymes involved in bacterial DNA replication. Examples include ciprofloxacin, moxifloxacin, and levofloxacin, which can be used as second-line treatments for drug-resistant TB.

These antitubercular drugs are often used in combination to prevent the development of drug resistance and improve treatment outcomes. The World Health Organization (WHO) recommends a standardized regimen consisting of isoniazid, rifampicin, ethambutol, and pyrazinamide for the initial two months, followed by isoniazid and rifampicin for an additional four to seven months. However, treatment regimens may vary depending on the patient's clinical presentation, drug susceptibility patterns, and local guidelines.

Haemophilus vaccines are vaccines that are designed to protect against Haemophilus influenzae type b (Hib), a bacterium that can cause serious infections such as meningitis, pneumonia, and epiglottitis. There are two main types of Hib vaccines:

1. Polysaccharide vaccine: This type of vaccine is made from the sugar coating (polysaccharide) of the bacterial cells. It is not effective in children under 2 years of age because their immune systems are not yet mature enough to respond effectively to this type of vaccine.
2. Conjugate vaccine: This type of vaccine combines the polysaccharide with a protein carrier, which helps to stimulate a stronger and more sustained immune response. It is effective in infants as young as 6 weeks old.

Hib vaccines are usually given as part of routine childhood immunizations starting at 2 months of age. They are administered through an injection into the muscle. The vaccine is safe and effective, with few side effects. Vaccination against Hib has led to a significant reduction in the incidence of Hib infections worldwide.

Poliovirus Vaccine, Inactivated (IPV) is a vaccine used to prevent poliomyelitis (polio), a highly infectious disease caused by the poliovirus. IPV contains inactivated (killed) polioviruses of all three poliovirus types. It works by stimulating an immune response in the body, but because the viruses are inactivated, they cannot cause polio. After vaccination, the immune system recognizes and responds to the inactivated viruses, producing antibodies that protect against future infection with wild, or naturally occurring, polioviruses. IPV is typically given as an injection in the leg or arm, and a series of doses are required for full protection. It is a safe and effective way to prevent polio and its complications.

Rabies vaccines are medical products that contain antigens of the rabies virus, which stimulate an immune response in individuals who receive them. The purpose of rabies vaccines is to prevent the development of rabies, a viral disease that is almost always fatal once symptoms appear.

There are two primary types of rabies vaccines available:

1. Pre-exposure prophylaxis (PrEP) vaccines: These vaccines are given to individuals who are at high risk of coming into contact with the rabies virus, such as veterinarians, animal handlers, and travelers visiting areas where rabies is common. The vaccine series typically consists of three doses given over a period of 28 days.
2. Post-exposure prophylaxis (PEP) vaccines: These vaccines are administered to individuals who have already been exposed to the rabies virus, usually through a bite or scratch from an infected animal. The vaccine series typically consists of four doses given over a period of 14 days, along with a dose of rabies immune globulin (RIG) to provide immediate protection while the immune system responds to the vaccine.

Both types of rabies vaccines are highly effective at preventing the disease, but it is essential to receive them as soon as possible after exposure or before potential exposure, as the virus can be fatal if left untreated.

Rotavirus vaccines are preventive measures used to protect against rotavirus infections, which are the leading cause of severe diarrhea and dehydration among infants and young children worldwide. These vaccines contain weakened or inactivated forms of the rotavirus, a pathogen that infects and causes symptoms by multiplying inside cells lining the small intestine.

The weakened or inactivated virus in the vaccine stimulates an immune response in the body, enabling it to recognize and fight off future rotavirus infections more effectively. The vaccines are usually administered orally, as a liquid droplet or on a sugar cube, to mimic natural infection through the gastrointestinal tract.

There are currently two licensed rotavirus vaccines available globally:

1. Rotarix (GlaxoSmithKline): This vaccine contains an attenuated (weakened) strain of human rotavirus and is given in a two-dose series, typically at 2 and 4 months of age.
2. RotaTeq (Merck): This vaccine contains five reassortant viruses, combining human and animal strains to provide broader protection. It is administered in a three-dose series, usually at 2, 4, and 6 months of age.

Rotavirus vaccines have been shown to significantly reduce the incidence of severe rotavirus gastroenteritis and related hospitalizations among infants and young children. The World Health Organization (WHO) recommends the inclusion of rotavirus vaccination in national immunization programs, particularly in countries with high child mortality rates due to diarrheal diseases.

Cholera vaccines are preventive measures used to protect against the infection caused by the bacterium Vibrio cholerae. There are several types of cholera vaccines available, including:

1. Inactivated oral vaccine (ICCV): This vaccine contains killed whole-cell bacteria and is given in two doses, with each dose administered at least 14 days apart. It provides protection for up to six months and can be given to adults and children over the age of one year.
2. Live attenuated oral vaccine (LCV): This vaccine contains weakened live bacteria that are unable to cause disease but still stimulate an immune response. The most commonly used LCV is called CVD 103-HgR, which is given in a single dose and provides protection for up to three months. It can be given to adults and children over the age of six years.
3. Injectable cholera vaccine: This vaccine contains inactivated bacteria and is given as an injection. It is not widely available and its effectiveness is limited compared to oral vaccines.

Cholera vaccines are recommended for travelers visiting areas with known cholera outbreaks, particularly if they plan to eat food or drink water that may be contaminated. They can also be used in response to outbreaks to help control the spread of the disease. However, it is important to note that vaccination alone is not sufficient to prevent cholera infection and good hygiene practices, such as handwashing and safe food handling, should always be followed.

Splenic tuberculosis is a form of extrapulmonary tuberculosis (ETB), which refers to a manifestation of the disease outside of the lungs. It is caused by the bacterium Mycobacterium tuberculosis.

In splenic tuberculosis, the infection involves the spleen (an organ located in the upper left part of the abdomen that filters blood and helps fight infection). The infection can occur through the hematogenous spread (dissemination via the bloodstream) from a primary focus elsewhere in the body, such as the lungs.

The disease presents with various symptoms, including fever, fatigue, weight loss, abdominal pain, and splenomegaly (enlargement of the spleen). Diagnosis often requires a combination of clinical evaluation, imaging studies, and microbiological or histopathological confirmation. Treatment typically involves a prolonged course of multidrug antibiotics to eliminate the infection and prevent complications.

Ocular tuberculosis (OTB) is a form of extrapulmonary tuberculosis (TB), which results from the spread of Mycobacterium tuberculosis complex bacteria outside the lungs. In ocular tuberculosis, these bacteria primarily affect the eye and its surrounding structures.

The most common form of OTB is tubercular uveitis, which involves inflammation of the uveal tract (iris, ciliary body, and choroid). Other forms of OTB include:

* Tubercular conjunctivitis: Inflammation of the conjunctiva, the mucous membrane that covers the front part of the eye and lines the inside of the eyelids.
* Tubercular keratitis: Inflammation of the cornea, the transparent outer layer at the front of the eye.
* Tubercular scleritis: Inflammation of the sclera, the white protective coating of the eye.
* Tubercular episcleritis: Inflammation of the episclera, a thin layer of tissue between the conjunctiva and sclera.
* Tubercular dacryoadenitis: Inflammation of the lacrimal gland, which produces tears.
* Tubercular optic neuritis: Inflammation of the optic nerve, which transmits visual information from the eye to the brain.

Diagnosis of OTB can be challenging due to its varied clinical presentations and the need for laboratory confirmation. A definitive diagnosis typically requires the isolation of Mycobacterium tuberculosis from ocular tissues or fluids, which may involve invasive procedures. In some cases, a presumptive diagnosis might be made based on clinical findings, epidemiological data, and response to anti-tuberculous therapy.

Treatment for OTB usually involves a standard anti-tuberculosis regimen consisting of multiple drugs (isoniazid, rifampin, ethambutol, and pyrazinamide) for at least six months. Corticosteroids or other immunosuppressive agents might be used concomitantly to manage inflammation and prevent tissue damage. Close monitoring is essential to ensure treatment adherence, assess response to therapy, and detect potential side effects.

Typhoid-Paratyphoid vaccines are immunizations that protect against typhoid fever and paratyphoid fevers, which are caused by the Salmonella enterica serovars Typhi and Paratyphi, respectively. These vaccines contain inactivated or attenuated bacteria or specific antigens that stimulate an individual's immune system to develop immunity against these diseases without causing the illness itself. There are several types of typhoid-paratyphoid vaccines available, including:

1. Ty21a (oral live attenuated vaccine): This is a live but weakened form of the Salmonella Typhi bacteria. It is given orally in capsule form and requires a series of 4 doses taken every other day. The vaccine provides protection for about 5-7 years.
2. Vi polysaccharide (ViPS) typhoid vaccine: This vaccine contains purified Vi antigens from the Salmonella Typhi bacterium's outer capsular layer. It is given as an injection and provides protection for approximately 2-3 years.
3. Combined typhoid-paratyphoid A and B vaccines (Vi-rEPA): This vaccine combines Vi polysaccharide antigens from Salmonella Typhi and Paratyphi A and B. It is given as an injection and provides protection for about 3 years against typhoid fever and paratyphoid fevers A and B.
4. Typhoid conjugate vaccines (TCVs): These vaccines combine the Vi polysaccharide antigen from Salmonella Typhi with a protein carrier to enhance the immune response, particularly in children under 2 years of age. TCVs are given as an injection and provide long-lasting protection against typhoid fever.

It is important to note that none of these vaccines provides 100% protection, but they significantly reduce the risk of contracting typhoid or paratyphoid fevers. Additionally, good hygiene practices, such as handwashing and safe food handling, can further minimize the risk of infection.

The Smallpox vaccine is not a live virus vaccine but is instead made from a vaccinia virus, which is a virus related to the variola virus (the virus that causes smallpox). The vaccinia virus used in the vaccine does not cause smallpox, but it does cause a milder illness with symptoms such as a fever and a rash of pustules or blisters at the site of inoculation.

The smallpox vaccine was first developed by Edward Jenner in 1796 and is one of the oldest vaccines still in use today. It has been highly effective in preventing smallpox, which was once a major cause of death and disability worldwide. In fact, smallpox was declared eradicated by the World Health Organization (WHO) in 1980, thanks in large part to the widespread use of the smallpox vaccine.

Despite the eradication of smallpox, the smallpox vaccine is still used today in certain circumstances. For example, it may be given to laboratory workers who handle the virus or to military personnel who may be at risk of exposure to the virus. The vaccine may also be used as an emergency measure in the event of a bioterrorism attack involving smallpox.

It is important to note that the smallpox vaccine is not without risks and can cause serious side effects, including a severe allergic reaction (anaphylaxis), encephalitis (inflammation of the brain), and myocarditis (inflammation of the heart muscle). As a result, it is only given to people who are at high risk of exposure to the virus and who have been determined to be good candidates for vaccination by a healthcare professional.

Bacterial antibodies are a type of antibodies produced by the immune system in response to an infection caused by bacteria. These antibodies are proteins that recognize and bind to specific antigens on the surface of the bacterial cells, marking them for destruction by other immune cells. Bacterial antibodies can be classified into several types based on their structure and function, including IgG, IgM, IgA, and IgE. They play a crucial role in the body's defense against bacterial infections and provide immunity to future infections with the same bacteria.

Antibodies, viral are proteins produced by the immune system in response to an infection with a virus. These antibodies are capable of recognizing and binding to specific antigens on the surface of the virus, which helps to neutralize or destroy the virus and prevent its replication. Once produced, these antibodies can provide immunity against future infections with the same virus.

Viral antibodies are typically composed of four polypeptide chains - two heavy chains and two light chains - that are held together by disulfide bonds. The binding site for the antigen is located at the tip of the Y-shaped structure, formed by the variable regions of the heavy and light chains.

There are five classes of antibodies in humans: IgA, IgD, IgE, IgG, and IgM. Each class has a different function and is distributed differently throughout the body. For example, IgG is the most common type of antibody found in the bloodstream and provides long-term immunity against viruses, while IgA is found primarily in mucous membranes and helps to protect against respiratory and gastrointestinal infections.

In addition to their role in the immune response, viral antibodies can also be used as diagnostic tools to detect the presence of a specific virus in a patient's blood or other bodily fluids.

Hepatic tuberculosis (HTB) is a form of extrapulmonary tuberculosis (TB) that involves the liver. It can occur as a result of the spread of Mycobacterium tuberculosis from a primary site of infection, usually the lungs, through the bloodstream to the liver.

In hepatic tuberculosis, the liver may become enlarged and tender, and patients may experience symptoms such as fever, night sweats, loss of appetite, weight loss, and abdominal discomfort. Liver function tests may show elevated levels of certain enzymes, such as alkaline phosphatase and gamma-glutamyl transferase (GGT).

Diagnosis of hepatic tuberculosis can be challenging, as the symptoms and laboratory findings are nonspecific. Imaging studies such as ultrasound, CT scan, or MRI may show evidence of liver involvement, but a definitive diagnosis usually requires histological examination of liver tissue obtained through biopsy.

Treatment of hepatic tuberculosis involves the use of multiple antituberculous drugs, typically including isoniazid, rifampin, ethambutol, and pyrazinamide. The duration of treatment is usually at least six months, but may be longer in some cases. It is important to monitor liver function tests closely during treatment, as these medications can cause liver damage in some individuals.

Female genital tuberculosis (FGTB) is a specific form of tuberculosis (TB) that affects the female reproductive organs. It is caused by the bacterium Mycobacterium tuberculosis, which primarily affects the lungs (pulmonary TB) but can spread to other parts of the body through the bloodstream or lymphatic system.

In FGTB, the bacteria typically infect the fallopian tubes, uterus, ovaries, and/or the cervix, leading to various gynecological symptoms. The infection can cause scarring, blockage of the fallopian tubes, and damage to the reproductive organs, which may result in infertility, ectopic pregnancy, or chronic pelvic pain.

FGTB is often asymptomatic or has non-specific symptoms, making it difficult to diagnose. Common symptoms include irregular menstrual bleeding, postmenopausal bleeding, vaginal discharge, and pelvic pain. Diagnosis typically involves a combination of clinical examination, imaging studies (such as ultrasound or CT scan), and laboratory tests (such as endometrial biopsy, PCR, or culture).

FGTB is usually treated with a standard anti-tuberculosis drug regimen that includes isoniazid, rifampicin, ethambutol, and pyrazinamide for at least six months. In some cases, surgery may be required to manage complications such as hydrosalpinx or chronic pelvic pain. Preventing the spread of pulmonary TB through early detection and treatment is crucial in preventing FGTB.

The chickenpox vaccine, also known as varicella vaccine, is a preventive measure against the highly contagious viral infection caused by the varicella-zoster virus. The vaccine contains a live but weakened form of the virus, which stimulates the immune system to produce a response without causing the disease itself.

The chickenpox vaccine is typically given in two doses, with the first dose administered between 12 and 15 months of age and the second dose between 4 and 6 years of age. In some cases, the vaccine may be given to older children, adolescents, or adults who have not previously been vaccinated or who have never had chickenpox.

The chickenpox vaccine is highly effective at preventing severe cases of the disease and reducing the risk of complications such as bacterial infections, pneumonia, and encephalitis. It is also effective at preventing transmission of the virus to others.

Like any vaccine, the chickenpox vaccine can cause mild side effects such as soreness at the injection site, fever, or a mild rash. However, these side effects are generally mild and short-lived. Serious side effects are rare but may include allergic reactions or severe immune responses.

Overall, the chickenpox vaccine is a safe and effective way to prevent this common childhood disease and its potential complications.

"Mycobacterium smegmatis" is a species of fast-growing, non-tuberculous mycobacteria (NTM). It is commonly found in the environment, including soil and water. This bacterium is known for its ability to form resistant colonies called biofilms. While it does not typically cause disease in humans, it can contaminate medical equipment and samples, potentially leading to misdiagnosis or infection. In rare cases, it has been associated with skin and soft tissue infections. It is often used in research as a model organism for studying mycobacterial biology and drug resistance due to its relatively harmless nature and rapid growth rate.

The Diphtheria-Tetanus-Pertussis (DTaP) vaccine is a combination immunization that protects against three bacterial diseases: diphtheria, tetanus (lockjaw), and pertussis (whooping cough).

Diphtheria is an upper respiratory infection that can lead to breathing difficulties, heart failure, paralysis, or even death. Tetanus is a bacterial infection that affects the nervous system and causes muscle stiffness and spasms, leading to "lockjaw." Pertussis is a highly contagious respiratory infection characterized by severe coughing fits, which can make it difficult to breathe and may lead to pneumonia, seizures, or brain damage.

The DTaP vaccine contains inactivated toxins (toxoids) from the bacteria that cause these diseases. It is typically given as a series of five shots, with doses administered at 2 months, 4 months, 6 months, 15-18 months, and 4-6 years of age. The vaccine helps the immune system develop protection against the diseases without causing the actual illness.

It is important to note that there are other combination vaccines available that protect against these same diseases, such as DT (diphtheria and tetanus toxoids) and Tdap (tetanus, diphtheria, and acellular pertussis), which contain higher doses of the diphtheria and pertussis components. These vaccines are recommended for different age groups and may be used as booster shots to maintain immunity throughout adulthood.

Ethambutol is an antimycobacterial medication used for the treatment of tuberculosis (TB). It works by inhibiting the synthesis of mycobacterial cell walls, which leads to the death of the bacteria. Ethambutol is often used in combination with other TB drugs, such as isoniazid and rifampin, to prevent the development of drug-resistant strains of the bacteria.

The most common side effect of ethambutol is optic neuritis, which can cause visual disturbances such as decreased vision, color blindness, or blurred vision. This side effect is usually reversible if the medication is stopped promptly. Other potential side effects include skin rashes, joint pain, and gastrointestinal symptoms such as nausea and vomiting.

Ethambutol is available in oral tablet and solution forms, and is typically taken once or twice daily. The dosage of ethambutol is based on the patient's weight, and it is important to follow the healthcare provider's instructions carefully to avoid toxicity. Regular monitoring of visual acuity and liver function is recommended during treatment with ethambutol.

The Mumps Vaccine is a biological preparation intended to induce immunity against mumps, a contagious viral infection that primarily affects the salivary glands. The vaccine contains live attenuated (weakened) mumps virus, which stimulates the immune system to develop a protective response without causing the disease.

There are two types of mumps vaccines available:

1. The Jeryl Lynn strain is used in the United States and is part of the Measles, Mumps, and Rubella (MMR) vaccine and the Measles, Mumps, Rubella, and Varicella (MMRV) vaccine. This strain is derived from a clinical isolate obtained from the throat washings of a child with mumps in 1963.
2. The Urabe AM9 strain was used in some countries but has been discontinued in many places due to an increased risk of meningitis as a rare complication.

The MMR vaccine is typically given to children at 12-15 months of age and again at 4-6 years of age, providing long-lasting immunity against mumps in most individuals. The vaccine has significantly reduced the incidence of mumps and its complications worldwide.

An immunization schedule is a series of planned dates when a person, usually a child, should receive specific vaccines in order to be fully protected against certain preventable diseases. The schedule is developed based on scientific research and recommendations from health organizations such as the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC).

The immunization schedule outlines which vaccines are recommended, the number of doses required, the age at which each dose should be given, and the minimum amount of time that must pass between doses. The schedule may vary depending on factors such as the individual's age, health status, and travel plans.

Immunization schedules are important for ensuring that individuals receive timely protection against vaccine-preventable diseases, and for maintaining high levels of immunity in populations, which helps to prevent the spread of disease. It is important to follow the recommended immunization schedule as closely as possible to ensure optimal protection.

Hepatitis A vaccines are inactivated or live attenuated viral vaccines that are administered to prevent infection and illness caused by the hepatitis A virus. The vaccine contains antigens that stimulate an immune response in the body, leading to the production of antibodies that protect against future infection with the virus.

The inactivated hepatitis A vaccine is made from viruses that have been chemically treated to destroy their ability to cause disease while preserving their ability to stimulate an immune response. This type of vaccine is typically given in two doses, six months apart, and provides long-term protection against the virus.

The live attenuated hepatitis A vaccine contains a weakened form of the virus that is unable to cause illness but can still stimulate an immune response. This type of vaccine is given as a single dose and provides protection against the virus for at least 20 years.

Hepatitis A vaccines are recommended for people who are at increased risk of infection, including travelers to areas where hepatitis A is common, men who have sex with men, people who use injection drugs, and people with chronic liver disease or clotting factor disorders. The vaccine is also recommended for children in certain states and communities where hepatitis A is endemic.

The Measles-Mumps-Rubella (MMR) vaccine is a combination immunization that protects against three infectious diseases: measles, mumps, and rubella. It contains live attenuated viruses of each disease, which stimulate an immune response in the body similar to that produced by natural infection but do not cause the diseases themselves.

The MMR vaccine is typically given in two doses, the first at 12-15 months of age and the second at 4-6 years of age. It is highly effective in preventing these diseases, with over 90% effectiveness reported after a single dose and near 100% effectiveness after the second dose.

Measles is a highly contagious viral disease that can cause fever, rash, cough, runny nose, and red, watery eyes. It can also lead to serious complications such as pneumonia, encephalitis (inflammation of the brain), and even death.

Mumps is a viral infection that primarily affects the salivary glands, causing swelling and tenderness in the cheeks and jaw. It can also cause fever, headache, muscle aches, and fatigue. Mumps can lead to serious complications such as deafness, meningitis (inflammation of the membranes surrounding the brain and spinal cord), and inflammation of the testicles or ovaries.

Rubella, also known as German measles, is a viral infection that typically causes a mild fever, rash, and swollen lymph nodes. However, if a pregnant woman becomes infected with rubella, it can cause serious birth defects such as hearing impairment, heart defects, and developmental delays in the fetus.

The MMR vaccine is an important tool in preventing these diseases and protecting public health.

Streptococcal vaccines are immunizations designed to protect against infections caused by Streptococcus bacteria. These vaccines contain antigens, which are substances that trigger an immune response and help the body recognize and fight off specific types of Streptococcus bacteria. There are several different types of streptococcal vaccines available or in development, including:

1. Pneumococcal conjugate vaccine (PCV): This vaccine protects against Streptococcus pneumoniae, a type of bacteria that can cause pneumonia, meningitis, and other serious infections. PCV is recommended for all children under 2 years old, as well as older children and adults with certain medical conditions.
2. Pneumococcal polysaccharide vaccine (PPSV): This vaccine also protects against Streptococcus pneumoniae, but it is recommended for adults 65 and older, as well as younger people with certain medical conditions.
3. Streptococcus pyogenes vaccine: This vaccine is being developed to protect against Group A Streptococcus (GAS), which can cause a variety of infections, including strep throat, skin infections, and serious diseases like rheumatic fever and toxic shock syndrome. There are several different GAS vaccine candidates in various stages of development.
4. Streptococcus agalactiae vaccine: This vaccine is being developed to protect against Group B Streptococcus (GBS), which can cause serious infections in newborns, pregnant women, and older adults with certain medical conditions. There are several different GBS vaccine candidates in various stages of development.

Overall, streptococcal vaccines play an important role in preventing bacterial infections and reducing the burden of disease caused by Streptococcus bacteria.

Directly Observed Therapy (DOT) is a treatment strategy in which a healthcare professional directly observes the patient taking each dose of their medication, typically used in the context of tuberculosis (TB) treatment. The goal of DOT is to ensure adherence to the prescribed treatment regimen and improve treatment outcomes by reducing the likelihood of missed doses or irregular medication-taking behaviors that can contribute to drug resistance and disease relapse.

In a DOT setting, the healthcare provider, which could be a nurse, community health worker, or other designated individual, directly observes the patient swallowing the medication. This can occur in various settings, such as a clinic, hospital, or even the patient's home, depending on the program and resources available. The frequency of observations may vary based on the specific treatment plan and clinical context.

DOT has been shown to improve treatment completion rates and reduce the risk of TB transmission and drug resistance. It is an essential component of the World Health Organization's (WHO) recommended strategy for TB control and care.

Endocrine tuberculosis (TB) is a form of extrapulmonary tuberculosis that involves the endocrine glands, such as the thyroid, pituitary, and adrenal glands. The infection can cause inflammation, granulomatous lesions, and tissue damage in these glands, leading to hormonal imbalances and various clinical manifestations.

Tuberculosis bacilli (Mycobacterium tuberculosis) reach the endocrine glands through hematogenous spread from a primary or secondary focus, usually in the lungs. The most common form of endocrine TB is adrenal TB, which can lead to adrenal insufficiency due to destruction of the adrenal cortex. Thyroid TB is rare and typically presents as a cold abscess or a thyroid mass. Pituitary TB is also uncommon but can cause hypopituitarism and visual impairment due to compression of the optic chiasm.

Diagnosis of endocrine TB often involves imaging studies, such as CT or MRI scans, hormonal assessments, and microbiological or histopathological examination of tissue samples obtained through biopsy. Treatment typically consists of a standard anti-tuberculous chemotherapy regimen, which may need to be adjusted based on the patient's hormonal status and clinical response.

Central Nervous System (CNS) Tuberculosis is a specific form of tuberculosis (TB) that refers to the infection and inflammation caused by Mycobacterium tuberculosis in the brain or spinal cord. The two most common forms of CNS tuberculosis are tuberculous meningitis and tuberculomas.

1. Tuberculous Meningitis (TBM): This is the most frequent form of CNS TB, characterized by the inflammation of the membranes surrounding the brain and spinal cord (meninges). The infection can lead to the formation of caseous lesions (granulomas), which may obstruct cerebrospinal fluid (CSF) flow and result in increased intracranial pressure. Symptoms often include headache, fever, altered mental status, neck stiffness, vomiting, and focal neurological deficits.
2. Tuberculomas: These are localized granulomatous lesions formed by the immune response to M. tuberculosis in the brain parenchyma. They can cause various neurological symptoms depending on their size and location, such as seizures, focal deficits, or increased intracranial pressure.

CNS TB is a severe manifestation of tuberculosis that requires prompt diagnosis and treatment to prevent long-term neurological damage or even death. Diagnosis typically involves imaging studies (CT or MRI scans) and analysis of cerebrospinal fluid obtained through lumbar puncture. Treatment usually consists of a prolonged course of multiple antituberculous drugs, along with corticosteroids to manage inflammation and prevent complications.

Immunization is defined medically as the process where an individual is made immune or resistant to an infectious disease, typically through the administration of a vaccine. The vaccine stimulates the body's own immune system to recognize and fight off the specific disease-causing organism, thereby preventing or reducing the severity of future infections with that organism.

Immunization can be achieved actively, where the person is given a vaccine to trigger an immune response, or passively, where antibodies are transferred to the person through immunoglobulin therapy. Immunizations are an important part of preventive healthcare and have been successful in controlling and eliminating many infectious diseases worldwide.

Anthrax vaccines are biological preparations designed to protect against anthrax, a potentially fatal infectious disease caused by the bacterium Bacillus anthracis. Anthrax can affect both humans and animals, and it is primarily transmitted through contact with contaminated animal products or, less commonly, through inhalation of spores.

There are two types of anthrax vaccines currently available:

1. Anthrax Vaccine Adsorbed (AVA): This vaccine is licensed for use in the United States and is approved for pre-exposure prophylaxis in high-risk individuals, such as military personnel and laboratory workers who handle the bacterium. AVA contains a cell-free filtrate of cultured B. anthracis cells that have been chemically treated to render them non-infectious. The vaccine works by stimulating the production of antibodies against protective antigens (PA) present in the bacterial culture.
2. Recombinant Anthrax Vaccine (rPA): This vaccine, also known as BioThrax, is a newer generation anthrax vaccine that was approved for use in the United States in 2015. It contains only the recombinant protective antigen (rPA) of B. anthracis, which is produced using genetic engineering techniques. The rPA vaccine has been shown to be as effective as AVA in generating an immune response and offers several advantages, including a more straightforward manufacturing process, fewer side effects, and a longer shelf life.

Both vaccines require multiple doses for initial immunization, followed by periodic booster shots to maintain protection. Anthrax vaccines are generally safe and effective at preventing anthrax infection; however, they may cause mild to moderate side effects, such as soreness at the injection site, fatigue, and muscle aches. Severe allergic reactions are rare but possible.

It is important to note that anthrax vaccines do not provide immediate protection against anthrax infection. They require several weeks to stimulate an immune response, so they should be administered before potential exposure to the bacterium. In cases of known or suspected exposure to anthrax, antibiotics are used as a primary means of preventing and treating the disease.

Dengue vaccines are designed to protect against dengue fever, a mosquito-borne viral disease that can cause severe flu-like symptoms and potentially life-threatening complications. Dengue is caused by four distinct serotypes of the virus (DENV-1, DENV-2, DENV-3, and DENV-4), and infection with one serotype does not provide immunity against the others.

The first licensed dengue vaccine, Dengvaxia (CYD-TDV), is a chimeric yellow fever-dengue tetravalent vaccine developed by Sanofi Pasteur. It is approved for use in several countries and has demonstrated efficacy against dengue fever caused by all four serotypes in clinical trials. However, the vaccine has raised concerns about the risk of severe disease in individuals who have not been previously exposed to dengue. As a result, it is recommended primarily for people with a documented past dengue infection or living in areas with high dengue prevalence and where the benefits outweigh the risks.

Another dengue vaccine candidate, Takeda's TAK-003 (also known as TDV), is a live attenuated tetravalent dengue vaccine that has shown efficacy against all four serotypes in clinical trials. It was granted approval by the European Medicines Agency (EMA) and several other countries for use in individuals aged 4-16 years old, living in endemic areas.

Research and development of additional dengue vaccine candidates are ongoing to address concerns about safety, efficacy, and accessibility, particularly for at-risk populations in low- and middle-income countries where dengue is most prevalent.

Laryngeal tuberculosis is a specific form of tuberculosis (TB), a bacterial infection caused by Mycobacterium tuberculosis, that affects the larynx or voice box. The bacteria typically infect the lungs, leading to pulmonary TB, and can spread through the bloodstream or airways to other parts of the body, including the larynx.

In laryngeal tuberculosis, the infection causes granulomatous inflammation and ulceration in the laryngeal tissues, particularly affecting the vocal cords, epiglottis, and/or false vocal cords. Symptoms may include hoarseness, cough, difficulty swallowing, painful swallowing, stridor (high-pitched whistling sound during breathing), and occasionally respiratory distress or airway obstruction. Diagnosis typically involves a combination of clinical evaluation, imaging studies (such as X-rays or CT scans), endoscopic examination, and microbiological or histopathological confirmation of the presence of TB in tissue samples or secretions. Treatment usually consists of a standard multidrug antituberculosis chemotherapy regimen to eliminate the infection and prevent complications or further spread of the disease.

Virosomes are artificially constructed spherical vesicles composed of lipids and viral envelope proteins. They are used as a delivery system for vaccines and other therapeutic agents. In the context of vaccines, virosomes can be used to present viral antigens to the immune system in a way that mimics a natural infection, thereby inducing a strong immune response.

Virosome-based vaccines have several advantages over traditional vaccines. For example, they are non-infectious, meaning they do not contain live or attenuated viruses, which makes them safer for certain populations such as immunocompromised individuals. Additionally, virosomes can be engineered to target specific cells in the body, leading to more efficient uptake and presentation of antigens to the immune system.

Virosome-based vaccines have been developed for a variety of diseases, including influenza, hepatitis A, and HIV. While they are not yet widely used, they show promise as a safe and effective alternative to traditional vaccine approaches.

Bacterial DNA refers to the genetic material found in bacteria. It is composed of a double-stranded helix containing four nucleotide bases - adenine (A), thymine (T), guanine (G), and cytosine (C) - that are linked together by phosphodiester bonds. The sequence of these bases in the DNA molecule carries the genetic information necessary for the growth, development, and reproduction of bacteria.

Bacterial DNA is circular in most bacterial species, although some have linear chromosomes. In addition to the main chromosome, many bacteria also contain small circular pieces of DNA called plasmids that can carry additional genes and provide resistance to antibiotics or other environmental stressors.

Unlike eukaryotic cells, which have their DNA enclosed within a nucleus, bacterial DNA is present in the cytoplasm of the cell, where it is in direct contact with the cell's metabolic machinery. This allows for rapid gene expression and regulation in response to changing environmental conditions.

Renal tuberculosis (TB) is a type of extrapulmonary tuberculosis that occurs when the Mycobacterium tuberculosis bacterium infects and affects the kidneys. It can also spread to other parts of the urinary system, such as the ureters, bladder, or urethra.

In renal TB, the infection typically begins in the renal cortex, where it causes caseous necrosis (formation of areas of tissue death) and granulomas (small clusters of immune cells). Over time, these lesions can lead to scarring, calcification, and destruction of renal tissues.

Symptoms of renal TB may include fever, fatigue, weight loss, flank pain, hematuria (blood in the urine), and sterile pyuria (pus in the urine without evidence of bacterial infection). Diagnosis typically involves a combination of medical history, physical examination, imaging studies (such as CT scans or intravenous pyelograms), and laboratory tests (such as urinalysis, acid-fast bacilli smears, and culture).

Treatment of renal TB usually involves a prolonged course of antibiotics (typically 6 to 9 months) using multiple drugs, such as isoniazid, rifampin, ethambutol, and pyrazinamide. Surgery may be necessary in some cases to remove damaged or infected tissues, or to relieve obstructions caused by scarring or calcification.

Molecular sequence data refers to the specific arrangement of molecules, most commonly nucleotides in DNA or RNA, or amino acids in proteins, that make up a biological macromolecule. This data is generated through laboratory techniques such as sequencing, and provides information about the exact order of the constituent molecules. This data is crucial in various fields of biology, including genetics, evolution, and molecular biology, allowing for comparisons between different organisms, identification of genetic variations, and studies of gene function and regulation.

Viral hepatitis vaccines are vaccines that prevent infection caused by various hepatitis viruses, including hepatitis A and B. These vaccines contain antigens that stimulate the immune system to produce antibodies that protect against infection with the corresponding virus. The vaccines are typically administered through injection and may require multiple doses for full protection.

The hepatitis A vaccine is made from inactivated hepatitis A virus, while the hepatitis B vaccine is made from recombinant hepatitis B surface antigen. Both vaccines have been shown to be highly effective in preventing infection and reducing the risk of complications associated with viral hepatitis, such as liver disease and liver cancer.

It's important to note that there are no vaccines available for other types of viral hepatitis, such as hepatitis C, D, or E. Prevention strategies for these types of viral hepatitis typically involve measures to reduce exposure to the virus, such as safe injection practices and avoiding high-risk behaviors like sharing needles or having unprotected sex with infected individuals.

Poliovirus Vaccine, Oral (OPV) is a vaccine used to prevent poliomyelitis (polio). It contains live attenuated (weakened) polioviruses, which stimulate an immune response in the body and provide protection against all three types of wild, infectious polioviruses. OPV is given by mouth, usually in drops, and it replicates in the gastrointestinal tract, where it induces a strong immune response. This response not only protects the individual who receives the vaccine but also helps to stop the spread of poliovirus in the community, providing indirect protection (herd immunity) to those who are not vaccinated. OPV is safe, effective, and easy to administer, making it an important tool for global polio eradication efforts. However, due to the risk of vaccine-associated paralytic polio (VAPP), inactivated poliovirus vaccine (IPV) is recommended for routine immunization in some countries.

The Yellow Fever Vaccine is a vaccine that protects against the yellow fever virus, which is transmitted to humans through the bites of infected mosquitoes. The vaccine contains live, weakened yellow fever virus, and it works by stimulating the immune system to produce an immune response that provides protection against the disease.

The yellow fever vaccine is recommended for people who are traveling to areas where yellow fever is common, including parts of Africa and South America. It is also required for entry into some countries in these regions. The vaccine is generally safe and effective, but it can cause mild side effects such as headache, muscle pain, and fever in some people. Serious side effects are rare, but may include allergic reactions or infection with the weakened virus used in the vaccine.

It's important to note that yellow fever vaccine may not be recommended for certain individuals, including infants younger than 6 months, pregnant women, people with weakened immune systems, and those with a history of severe allergic reaction to a previous dose of the vaccine or any component of the vaccine. It is always best to consult with a healthcare provider before receiving any vaccination.

A plague vaccine is a type of immunization used to protect against the bacterial infection caused by Yersinia pestis, the causative agent of plague. The vaccine contains killed or weakened forms of the bacteria, which stimulate the immune system to produce antibodies and activate immune cells that can recognize and fight off the infection if the person is exposed to the bacteria in the future.

There are several types of plague vaccines available, including whole-cell killed vaccines, live attenuated vaccines, and subunit vaccines. The choice of vaccine depends on various factors, such as the target population, the route of exposure (e.g., respiratory or cutaneous), and the desired duration of immunity.

Plague vaccines have been used for many years to protect military personnel and individuals at high risk of exposure to plague, such as laboratory workers and people living in areas where plague is endemic. However, their use is not widespread, and they are not currently recommended for general use in the United States or other developed countries.

It's important to note that while plague vaccines can provide some protection against the disease, they are not 100% effective, and other measures such as antibiotics and insect control are also important for preventing and treating plague infections.

HIV (Human Immunodeficiency Virus) infection is a viral illness that progressively attacks and weakens the immune system, making individuals more susceptible to other infections and diseases. The virus primarily infects CD4+ T cells, a type of white blood cell essential for fighting off infections. Over time, as the number of these immune cells declines, the body becomes increasingly vulnerable to opportunistic infections and cancers.

HIV infection has three stages:

1. Acute HIV infection: This is the initial stage that occurs within 2-4 weeks after exposure to the virus. During this period, individuals may experience flu-like symptoms such as fever, fatigue, rash, swollen glands, and muscle aches. The virus replicates rapidly, and the viral load in the body is very high.
2. Chronic HIV infection (Clinical latency): This stage follows the acute infection and can last several years if left untreated. Although individuals may not show any symptoms during this phase, the virus continues to replicate at low levels, and the immune system gradually weakens. The viral load remains relatively stable, but the number of CD4+ T cells declines over time.
3. AIDS (Acquired Immunodeficiency Syndrome): This is the most advanced stage of HIV infection, characterized by a severely damaged immune system and numerous opportunistic infections or cancers. At this stage, the CD4+ T cell count drops below 200 cells/mm3 of blood.

It's important to note that with proper antiretroviral therapy (ART), individuals with HIV infection can effectively manage the virus, maintain a healthy immune system, and significantly reduce the risk of transmission to others. Early diagnosis and treatment are crucial for improving long-term health outcomes and reducing the spread of HIV.

Sensitivity and specificity are statistical measures used to describe the performance of a diagnostic test or screening tool in identifying true positive and true negative results.

* Sensitivity refers to the proportion of people who have a particular condition (true positives) who are correctly identified by the test. It is also known as the "true positive rate" or "recall." A highly sensitive test will identify most or all of the people with the condition, but may also produce more false positives.
* Specificity refers to the proportion of people who do not have a particular condition (true negatives) who are correctly identified by the test. It is also known as the "true negative rate." A highly specific test will identify most or all of the people without the condition, but may also produce more false negatives.

In medical testing, both sensitivity and specificity are important considerations when evaluating a diagnostic test. High sensitivity is desirable for screening tests that aim to identify as many cases of a condition as possible, while high specificity is desirable for confirmatory tests that aim to rule out the condition in people who do not have it.

It's worth noting that sensitivity and specificity are often influenced by factors such as the prevalence of the condition in the population being tested, the threshold used to define a positive result, and the reliability and validity of the test itself. Therefore, it's important to consider these factors when interpreting the results of a diagnostic test.

A fungal vaccine is a biological preparation that provides active acquired immunity against fungal infections. It contains one or more fungal antigens, which are substances that can stimulate an immune response, along with adjuvants to enhance the immune response. The goal of fungal vaccines is to protect against invasive fungal diseases, especially in individuals with weakened immune systems, such as those undergoing chemotherapy, organ transplantation, or HIV/AIDS treatment.

Fungal vaccines can work by inducing both humoral and cell-mediated immunity. Humoral immunity involves the production of antibodies that recognize and neutralize fungal antigens, while cell-mediated immunity involves the activation of T cells to directly attack infected cells.

Currently, there are no licensed fungal vaccines available for human use, although several candidates are in various stages of development and clinical trials. Some examples include vaccines against Candida albicans, Aspergillus fumigatus, Cryptococcus neoformans, and Pneumocystis jirovecii.

Table 1. Global clinical tuberculosis vaccine pipeline. Phase I. Phase IIa. Phase IIb. Phase III. ... Recent Developments in Clinical Trials in the Current Global Tuberculosis Vaccine Portfolio ... Recent Developments in Clinical Trials in the Current Global Tuberculosis Vaccine Portfolio ... Biomarkers in clinic are needed for prediction of vaccine efficacy against TB vaccine evaluation and to shorten costly efficacy ...
2022)‎. An investment case for new tuberculosis vaccines. World Health Organization. https://apps.who.int/iris/handle/10665/ ...
... status of TB vaccine development, preclinical obstacles for TB candidate vaccines, challenges in TB vaccine evaluation, ... Notice to Readers International Symposium on Tuberculosis Vaccine Development and Evaluation The 1998 International Symposium ... on Tuberculosis Vaccine Development and Evaluation will be held August 26-28, 1998, in San Francisco, California. The symposium ... Information on the symposium is available from CDCs National Vaccine Program Office, telephone (404) 639-4168. ...
... mainly because of the lack of a safe and efficacious vaccine to control tuberculosis. An effective vaccine will likely induce ... In addition, the RFA title "Tuberculosis Vaccine Development" and number (AI-93-02) must be typed on line 2a of the face page ... This RFA, Tuberculosis Vaccine Development, is related to the priority areas immunization and infectious diseases. Potential ... Full Text AI-93-02 TUBERCULOSIS VACCINE DEVELOPMENT NIH GUIDE, Volume 21, Number 45, December 18, 1992 RFA: AI-93-02 P.T. 34 ...
... scientists have developed a vaccine that provides superior protection against long-term disease. ... By combining 3 proteins expressed by tuberculosis bacteria at different disease stages, ... New Vaccine Offers Better Protection Against Tuberculosis. Microscope image of red-stained TB bacteria.Dr. George P. Kubica, ... Scientists have developed a new tuberculosis vaccine that targets proteins from both early and later stages of the disease. The ...
WHO preferred product characteristics for new tuberculosis vaccines  World Health Organization (‎World Health Organization, ... Preferred product characteristics for therapeutic vaccines to improve tuberculosis treatment outcomes  World Health ... Estrategia mundial de investigación e innovación contra la tuberculosis  Organización Mundial de la Salud (‎Organización ... Proceedings of the fourth Global Vaccine Research Forum  World Health Organization (‎World Health OrganizationWorld Health ...
An overview of NIAIDs commitment to the global research communitys focus on finding new ways to prevent tuberculosis (TB) ... Tuberculosis Vaccine Development. NIAID is part of the global research community engaged in finding new ways to prevent ... NIAID is providing support to help identify and evaluate new candidate TB vaccines and immune-boosting vaccine adjuvants to ... An effective vaccine is considered to be one of the most essential tools needed to reduce this deadly disease worldwide. It is ...
... tuberculosis-based vaccine to enter clinical trials". Vaccine. 31 (42): 4867-4873. doi:10.1016/j.vaccine.2013.07.051. PMID ... Tuberculosis (TB) vaccines are vaccinations intended for the prevention of tuberculosis. Immunotherapy as a defence against TB ... Today, the only effective tuberculosis vaccine in common use is the Bacillus Calmette-Guérin (BCG) vaccine, first used on ... MVA85A rBCG30 72F fusion protein MTBVAC New vaccines are being developed by the Tuberculosis Vaccine Initiative, including TBVI ...
... more effective vaccines against TB (7,8). Vaccines currently under development include subunit vaccines (9), naked DNA vaccines ... Gates grant boosts tuberculosis vaccine research. US82.0 million dollars grant will double global spending on new tuberculosis ... Flow-diagram of preexposure tuberculosis (TB) vaccine model. States and processes that relate to the vaccine are shown in red. ... Flow-diagram of preexposure tuberculosis (TB) vaccine model. States and processes that relate to the vaccine are shown in red. ...
Mycobacterium tuberculosis,/i,. As a result of the coronavirus disease 2019 (COVID-19) pandemic, the global TB mortality rate ... Tuberculosis (TB) is an infectious disease caused by ,i, ... Peptide-Based Vaccines for Tuberculosis Wenping Gong 1 , Chao ... Multi-stage subunit vaccines against Mycobacterium tuberculosis: an alternative to the BCG vaccine or a BCG-prime boost? ... Peptide-Based Vaccines for Tuberculosis Wenping Gong et al. Front Immunol. 2022. . ...
... the primary lesions of mycobacterium tuberculosis (TB) heal completely and leave no clinical evidence of prior infection except ... Mycobacterium tuberculosis - Vaccines for the 21st Century. Mycobacterium tuberculosis - Vaccines for the 21st Century. ... The Role of BCG Vaccine in the Prevention and Control of Tuberculosis in the United States. Morbidity and Mortality Weekly ... If a vaccine program for TB were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target ...
Impeded Immunity? Reduced Tuberculosis Vaccine Response with Exposure to Environmental Chemicals. *is accompanied by*A Birth ... 1 Grandjean Pet al. Serum vaccine antibody concentrations in children exposed to perfluorinated compounds. JAMA 307(4):391-397 ... 6 Trunz BBet al. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta- ... A Birth Cohort Study of Maternal and Infant Serum PCB-153 and DDE Concentrations and Responses to Infant Tuberculosis ...
... currently the only TB vaccine available. BCG was developed in the 1920s and has been used worldwide. The new ... A new vaccine has been developed to act as a booster to Bacille Calmette Guerin (BCG), ... New tuberculosis vaccine developed. Date:. October 1, 2013. Source:. McMaster University. Summary:. A new vaccine has been ... A tuberculosis vaccine developed at McMaster University offers new hopes for the global fight against tuberculosis. ...
A Joint Statement by the ACIP and the Advisory Committee for Elimination of Tuberculosis ... Use of BCG Vaccines in the Control of Tuberculosis: ... ACIP: Use of BCG Vaccines in the Control of Tuberculosis: A ... Trial of BCG vaccines in south India for tuberculosis prevention: tuberculosis prevention trial, Madras. Indian J Med Res 1980; ... Replaces previous recommendation on BCG vaccines (MMWR 1979;28:241-4). References. * Romanus V. Tuberculosis in Bacillus ...
bcg_vaccine. :. head(bcg_vaccine) #, studyn trtn trtc latitude r n #, 1 1 1 Unvaccinated 44 11 139 #, 2 1 2 Vaccinated 44 4 123 ... Example: BCG vaccine for tuberculosis. library(multinma) options(mc.cores = parallel::detectCores()). ... bcg_net ,- set_agd_arm(bcg_vaccine, study = studyn, trt = trtc, r = r, n = n, trt_ref = Unvaccinated) bcg_net #, A network ... vaccine %,% group_by(studyn) %,% mutate(lor = log(r / (n - r)) - log(first(r) / (first(n) - first(r))), sample_size = sum(n)) ...
... tuberculosis infection in humans. However, this vaccine provides a limited protection against tuberculosis in children. In ... Vaccines Against Tuberculosis. Author(s): Thaynan Sama Alves de Oliveira and Michelle Christiane da Silva Rabello ... Vaccines Against Tuberculosis, Tropical Diseases: An Overview of Major Diseases Occurring in the Americas (2017) 1: 467. https ... Therefore, the development of new vaccines to increase the efficacy of vaccination against tuberculosis is urgently required. ...
... and preparation of clinical material of the tuberculosis vaccine candidate ID93 / GLA-SE. The tuberculosis vaccine has reached ... Long-term stability of the thermostable tuberculosis vaccine formulation was demonstrated with 24 months stability when stored ... a Single-Vial Adjuvanted Subunit Tuberculosis Vaccine Candidate for Use in Clinical Studies" in Frontiers In Drug Delivery, ... This work represents the first advancement of a thermostable adjuvant-containing subunit tuberculosis vaccine to clinical study ...
Vaccine Inequality Fuels Suspicion and Division. The world cant repeat the mistakes of polio, tuberculosis, and measles. By ... vaccine-coronavirus-pandemic-covid-19-foreign-policy-illustration. The World Is Winning-and Losing-the Vaccine Race. ... The bacille Calmette-Guérin vaccine for tuberculosis was developed almost a century ago, but in the time since then, millions ... which is developing its own COVID-19 vaccine, in Siberia, Vektor on May 20.. Kremlin Spin Doctors are Leading Russias Vaccine ...
... the normal mode analysis of the S7D5L4 vaccine and toll-like receptor 4 docking simulation demonstrated that the vaccine had ... 4) Conclusions: The S7D5L4 vaccine designed to fight against the co-infection of MTB and SARS-CoV-2 may be safe and effective. ... This study aims to design an effective preventive multi-epitope vaccine against the co-infection of MTB and SARS-CoV-2. (2) ... This vaccine had excellent antigenicity and immunogenicity and could successfully simulate immune responses in silico. ...
The Tuberculosis Vaccines Analysis report offers an entire substantial study of the Tuberculosis Vaccines market, key tactics ... the Tuberculosis Vaccines Market research report summarizes some of the leading enterprises in the Tuberculosis Vaccines ... market.biz/report/global-tuberculosis-vaccines-market-qy/334533/#inquiry. Tuberculosis Vaccines Marketing Analysis and ... Request a sample Report of Tuberculosis Vaccines Market: https://market.biz/report/global-tuberculosis-vaccines-market-qy/ ...
5 more authors) (2020) Evaluation of the efficacy of RUTI and ID93/GLA-SE vaccines in tuberculosis treatment : in silico trial ... Evaluation of the efficacy of RUTI and ID93/GLA-SE vaccines in tuberculosis treatment : in silico trial through UISS-TB ... To address this alarming burden, vaccines can play a fundamental role, even though to date no fully effective TB vaccine really ... two specific tuberculosis vaccines. Such an in silico trial will be validated through a phase 2b clinical trial. Moreover, ...
Researchers have now created an effective vaccine against this deadly and highly infectious disease. ... Tuberculosis has hit one in three persons in the world. ... New vaccine could eradicate tuberculosis. Tuberculosis has hit ... A new vaccine against tuberculosis is currently being tested on humans in South Africa. The vaccine, known as H56, could be the ... In order to eradicate tuberculosis, we need the new H56 in combination with chemotherapy. The vaccine will protect some people ...
Encapsulating Nanoparticles Enhance Innate Immune Responses to the Tuberculosis Vaccine Bacille Calmette-Guérin (BCG) via ... The attenuated live vaccine strain bacille Calmette-Guérin (BCG) is currently the only available vaccine against tuberculosis ... Poly(I:C)-Encapsulating Nanoparticles Enhance Innate Immune Responses to the Tuberculosis Vaccine Bacille Calmette-Guérin (BCG ... mouse BMDMpIC-NP stimulusTLR activationTRIF-dependent TLRIFNBCG-vaccine immunogenicityMyD 88-Innate Immune Receptorschitosan- ...
1935: Tuberculosis vaccine tested on American Indians. American Indians enroll in an experimental study to determine the ... Timeline / Citizenship, Services, and Sovereignty / 1935: Tuberculosis vaccine tested on American Indians ... effectiveness of a tuberculosis vaccine developed 14 years earlier in France. More than 3,000 receive a single dose of the ... In 2004, a study of medical and death records of the American Indians who received the Bacille Calmette Guérin vaccine in the ...
... InfectionsTuberculosis ... Potential vaccine readies immune system to kill tuberculosis in mice. • Infections • • Tuberculosis • Sep 05, 11 ... A potential vaccine against tuberculosis has been found to completely eliminate tuberculosis bacteria from infected tissues in ... California high school to test students for tuberculosis. TB Vaccine May Work Against Multiple Sclerosis. Tuberculosis: Nature ...
... more effective vaccines against TB (7,8). Vaccines currently under development include subunit vaccines (9), naked DNA vaccines ... Gates grant boosts tuberculosis vaccine research. US82.0 million dollars grant will double global spending on new tuberculosis ... Flow-diagram of preexposure tuberculosis (TB) vaccine model. States and processes that relate to the vaccine are shown in red. ... Flow-diagram of preexposure tuberculosis (TB) vaccine model. States and processes that relate to the vaccine are shown in red. ...
There is currently only a single vaccine against tuberculosis, the (Bacillus Calmette-Guérin) BCG vaccine. Reports suggest ... This CDC-developed technology relates to novel vaccines or boosters directed against pulmonary tuberculosis. ... Versatile, has potential as stand-alone vaccine or booster for use with current BCG vaccine ... tuberculosis. These improvements may be implemented as stand-alone vaccines or in conjunction with BCG as part of a prime-boost ...
MVA85A is a subunit vaccine that could enhance immunity from BCG vaccination. To determine MVA85A safety and immunogenicity as ... Coadministration of MVA85A with EPI vaccines was associated with a significant reduction in MVA85A immunogenicity, but did not ... vaccines alone, EPI and MVA85A simultaneously, or MVA85A alone. Adverse events were monitored throughout. Blood samples ... that modifications to the standard EPI schedule may be required to incorporate a new generation of T cell-inducing vaccines. ...

No FAQ available that match "tuberculosis vaccines"

No images available that match "tuberculosis vaccines"